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ABSTRACT OF THE THESIS 
 
Phenotyping Double Transgenic Mouse Models of Alzheimer’s that Express Human APP 
and ApoE3 or ApoE4 
 
by 
Shina Halavi 
Doctor of Philosophy, Graduate Program in Clinical Psychology 
Loma Linda University, June 2016 
Dr. Richard Hartman, Chairperson 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes progressive 
cognitive and behavioral problems resulting from a build-up of amyloid-beta (Aβ) 
plaques in the brain. The degree of neuropathology is partially related to apolipoprotein E 
(apoE), a fat-binding protein involved in transporting cholesterol to neurons. The APOE 
gene, which codes for the production of apoE, has several alleles in humans, including 
APOE3 (E3; the most common) and APOE4 (E4; which is associated with a high risk for 
developing AD). 
 Transgenic mouse models of AD are commonly used to study the 
neuropathological processes behind the development of Aβ plaques, neurodegeneration, 
and associated behavioral deficits. The current study was designed to determine whether 
expression of E4 in a transgenic mouse model of AD (the PDAPP mouse) alters these 
processes in a way that replicates the effects observed in humans with E4. The brains of 
male PDAPP x APOE3 mice (PDAPP:E3; n=5) were compared to those of PDAPP x 
APOE4 mice (PDAPP:E4; n=4) by staining tissue sections with HJ3.4, thioflavin-S, and 
4’,6-diamidino-2-phenylindole (DAPI) to quantify diffuse Aβ, fibrillar Aβ, and cellular 
count, respectively.  
 xii 
 PDAPP:E4 mice had more total Aβ in the CA1 of the hippocampus and dorsal 
cortex. Also, a trend suggested PDAPP:E4 mice had a lower cellular density in the CA1 
and dorsal cortex than PDAPP:E3 mice. Importantly, more Alzheimer’s-like 
neuropathology was generally associated with worse behavioral deficits. Since these 
results replicate aspects of human AD (plaque load, lower cellular density, and behavioral 
deficits), the expression of human APOE in transgenic mice may improve their use as a 
model system for understanding the processes involved in the development of AD and 
therapeutic strategies for dealing with the disease. 
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CHAPTER ONE 
SPECIFIC AIMS 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized by global cognitive decline involving memory, orientation, judgment and 
reasoning. AD is the most common cause of dementia, a decline in mental ability due to a 
brain disease or injury, in the elderly. In 2014, the Alzheimer’s Association estimated that 
5.2 million Americans had AD (2014 Alzheimer’s Disease Facts and Figures, 2014). In 
familial AD (FAD, or early-onset AD), which is directly caused by an autosomal 
dominant gene mutation, an abnormal variation of the amyloid precursor protein gene 
(APP) gets cleaved by β- and γ-secretase, releasing a free Aβ peptide from the protein. 
These Aβ peptides aggregate, which lead to the accumulation of Aβ plaques in the brain, 
which eventually causes neuronal dysfunction in the brain. This form of AD accounts for 
about 1-5% of all cases of AD (Demattos, Bales, Paul, & Holtzman, 2000).  
In the more common (“sporadic”, or late onset) form of AD, genes can also 
influence the risk of developing the disease. The most-studied gene of susceptibility for 
sporadic AD is the APOE gene, which codes for the protein apolipoprotein E (apoE). 
APOE plays a role in the pathogenesis of late-onset AD, and has three major alleles: 
APOE2 (E2), APOE3 (E3), and APOE4 (E4). Alleles are alternative forms of a gene that 
arise by a mutation and are found on the same place on the chromosome. Each individual 
carries two copies of APOE, one from each parent. The likelihood of someone 
developing AD is highly dependent upon which of these three alleles they carry (Corder 
et al., 1993). The current study addresses E4, which is known to increase the risk and 
decrease the age of onset of AD, and E3, which encodes for the most common isoform 
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(apoE3) and acts as a neutral allele, not influencing one’s risk of developing the disease 
by using a double-transgenic mouse model. ApoE “knockout” (KO) mice, which do not 
express APOE, had human E3 and E4 inserted into their genomes via “knockin” (KI) 
technology. These models address a novel way of producing double-transgenic mice, 
representing a “cleaner” double-transgenic mouse model compared to what is normally 
seen in the literature (e.g., Hartman et al., 2002). This methodology differs from what is 
normally seen in the literature in that human APOE was not placed in a random location, 
but in the exact location within the mouse genome from which murine APOE was 
removed. Hypothetically, this resulted in an Aβ and APOE interaction more similar to 
what is seen in humans with AD. These mice were then crossbred with PDAPP 
transgenic mice, the first successful AD transgenic mouse model that contained an FAD-
associated mutation (Games et al., 1995).  
 My hypothesis is that PDAPP mice that also express human E4 will have more 
Alzheimer’s-like neuropathology than PDAPP mice that express human E3. The 
objective of this study is to determine whether targeted expression of human APOE alters 
neuropathology in a transgenic mouse model of AD by establishing a baseline 
neuropathological and behavioral data for a new double-transgenic mouse model of AD. 
Neuropathological assessment of PDAPP mice expressing human E3 and E4 has 
consisted of thioflavin-S staining (Kelly R. Bales et al., 1999; Fagan et al., 2002; Richard 
E Hartman et al., 2002). Bales et al. (1999) found that the amount of fibrillar amyloid 
(thioflavin-S-positive material) was significantly greater in PDAPP:E4 mice than in the 
PDAPP:E3 mice. Fagan et al. (2002) found that PDAPP:E4 mice had a greater Aβ burden 
and an earlier age of onset than the PDAPP:E3 mice. Lastly, Hartman et al. (2002) 
 3 
assessed the effects of TBI (traumatic brain injury) in PDAPP:E4 and PDAPP:E3 mice 
and only found thioflavin-S-positive Aβ (amyloid) in the PDAPP/ε4 mice. Behavioral 
assessments of APOE transgenic mice have consisted of spatial learning and memory 
tests (rotating holeboard, radial arm maze, and water maze) and tests of sensorimotor 
capabilities and emotionality (locomotor activity and elevated plus maze) (R E Hartman 
et al., 2001). This objective will be met by addressing the following three aims.  
 
Aim 1: To determine whether expression of human APOE will alter plaque load in 
the hippocampus and dorsal cortex of double-transgenic mice that model aspects of 
AD. Hypothesis: PDAPP mice that also express human E4 will have more amyloid-beta 
(Aβ) plaques in their brains than PDAPP mice that also express human E3. Rationale: 
Humans with 1 or 2 copies of the E4 gene generally have worse Alzheimer’s 
neuropathology than humans without E4. 
 
Aim 2: To determine whether expression of human APOE will alter cellular density 
in the CA1 region of the hippocampus and dorsal cortex of transgenic mice that 
model aspects of Alzheimer’s disease. Hypothesis: PDAPP mice that also express 
human E3 will have a lower cellular density in the CA1 region of the hippocampus and 
dorsal cortices than PDAPP mice that also express human E3. Rationale: Humans with 1 
or 2 copies of the E4 gene generally have more Aβ aggregates, leading to a greater 
cellular loss. 
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Aim 3: To determine whether the degree of neuropathology is correlated with 
behavioral deficits observed in these mice. Hypothesis: Mice with more Alzheimer’s-
like neuropathology (specifically Aβ plaques and/or neuronal loss) will have worse 
behavioral deficits. Rationale: The formation of Aβ plaques in humans is thought to 
ultimately lead to the neuronal dysfunction and cognitive deficits observed in AD. 
  
 5 
CHAPTER TWO 
SIGNIFICANCE 
Demographics 
In 2014, the Alzheimer’s Association reported that AD affects 11% of people 65 
years and older and 32% of people 85 years and older (2014 Alzheimer’s Disease Facts 
and Figures, 2014). In 2012, the Alzheimer’s Association estimated that, of those with 
AD, 4% are under the age of 65, 6% are 65 to 74 years of age, 44% are 75 to 84 years of 
age, and 46% are 85 years or older (2012 Alzheimer’s disease facts and figures, 2012). In 
addition to the high prevalence of AD (number of existing cases in a population at a 
given time), the estimated annual incidence (rate of developing AD in a one-year period) 
of AD appears to increase dramatically with age. The Journal of Alzheimer Disease and 
Associated Disorders estimated that by the year 2050, there would be 80 new cases of 
AD per 1,000 people age 65 to 74, to 282 new cases per 1,000 people age 75 to 84, to 598 
new cases per 1,000 people over age 85. This increasing incidence rate is due to an aging 
population and social and environmental factors. The increasingly high prevalence and 
incidence rate of this disease is concerning, emphasizing the importance of the 
development of effective treatments. 
 
Neuropathology 
Plaques 
Amyloid plaques are a neuropathological characteristic of AD (Calhoun et al., 
1998). Amyloid plaques are formed by Aβ, a 39-to-43-amino-acid-long peptide derived 
by the proteolytic processing of APP. When APP is cleaved by β- and γ-secretase, Aβ 
 6 
gets released into the extracellular space (Figure 1; Haass et al., 1992; Martin et al., 1995; 
Shoji et al., 2014; Wertkin et al., 1993; Yang, Knauer, Burdick, & Glabe, 1995), 
normally via synaptic activity (Kamenetz et al., 2003). Another enzyme, α-secretase, 
serves as a neuroprotectant by cleaving the APP molecule within the Aβ peptide region, 
preventing the formation of Aβ plaques. 
 
 
 
Figure 1. β- and γ-secretase cleave APP at specific sites to form toxic Aβ. Retrieved 
from http://commons.wikimedia.org/wiki/File:APP_cleavage_produce_toxic_Abeta.png. 
 
 
The two most common isoforms of Aβ are Aβ40 and Aβ42, which only differ by 
two amino acids (Yan & Wang, 2006). Aβ40 is a 40-residue soluble peptide, which 
represents the most abundant Aβ isoform, both in the normal and AD brain (Mori, Takio, 
Ogawarag, & Selkoe, 1992), especially in sporadic AD (Näslund et al., 1994). Aβ42 is a 
42-residue insoluble peptide, which is more closely linked to FAD (Younkin, 1998). Aβ42 
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has shown to form insoluble amyloid fibrils more rapidly than the abundant Aβ40, making 
it more susceptible to fibril formation in both humans and mice (Hartman et al., 2005; 
Jarrett, Berger, & Lansbury, 1993).  
Amyloid fibrils are formed by soluble proteins that aggregate to form insoluble 
fibers, which are resistant to degradation (Rambaran & Serpell, 2008). Amyloid is 
dominated by a β-pleated sheet structure, which consists of the protein being folded in a 
certain way that gives it a very stable structure (Rambaran & Serpell, 2008). This process 
is also seen in the production of spider silk, where soluble proteins are converted to 
“stronger than steel” insoluble fibers (Kenney, Knight, Wise, & Vollrath, 2002). The 
spider silk also takes on a β-pleated sheet structure (Kenney et al., 2002). Aβ42 is 
particularly known to be neurotoxic (Elder, Sosa, & Gasperi, 2010; Yan & Wang, 2006) 
and more prone to aggregation than Aβ40 (Yan & Wang, 2006). Aβ42 has specifically been 
described as the more toxic form of Aβ (Querfurth & Laferla, 2010; reviewed [Tai, 
Youmans, Jungbauer, Yu, & Ladu, 2011]).  
The elevated Aβ levels in the brain drive the conversion of soluble forms of Aβ to 
aggregated forms of Aβ (Holtzman, 2004), forming amyloid plaques within the 
extracellular spaces of the brain. Amyloid plaques exist in different conformations. These 
conformations include diffuse plaques, compact plaques, and neuritic plaques in 
increasing chronological and neuropathological order (Groen, Liu, Ikonen, & Kadish, 
2003). Diffuse plaques, which contain nonfibrillar Aβ, develop from aggregated soluble 
peptides. Diffuse plaques are displayed as amorphous wisps of amyloid that lack a central 
core and are probably not neurotoxic. The reason they are important to be studied is 
because of their progression into neurotoxic plaques. Diffuse plaques have a low β-
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pleated sheet content (Holtzman, 2004). Compact “amyloid” plaques are composed of a 
dense thioflavin-S-positive core, and neuritic plaques are identified as amyloid plaques 
surrounded by a ring of dystrophic neurites (axons/dendrites; (Groen et al., 2003). 
Compact and neuritic plaques contain fibrillar Aβ, which possess a high β-pleated sheet 
structure (Holtzman, 2004; Mattson, 1997). 
As described by Games et al. (1995), it is the enhanced production of Aβ peptide 
(specifically Aβ42) that leads to the pathological deposition of amyloid in the brain. It is 
the accumulation of these Aβ deposits in the brain that leads to the development of the 
Aβ plaques that eventually lead to neuronal dysfunction in the brain (Koudinov, Berezov, 
& Koudinova, 2001). Although the mechanism of amyloid neurotoxicity remains unclear 
(Stern et al., 2004; reviewed [Tai et al., 2011]; Verghese, Castellano, & Holtzman, 2011), 
research suggests that Aβ has been found in mitochondrial membranes, impairing 
mitochondrial function (Lustbader et al., 2004; Mattson, Partin, & Begley, 1998; Reddy, 
2009). Mitochondria are the major source of energy for normal functioning brain cells. 
However, evidence linking Aβ toxicity with mitochondrial dysfunction is still limited to 
in vitro studies. Stern et al. (2004) has also suggested that the Aβ plaques disrupt the 
synchrony of convergent inputs, reducing the ability of neurons to successfully integrate 
and propagate information. Amyloid deposition in the brain’s parenchyma and cerebral 
blood vessels is one of the recognized neuropathological features of AD. These distinct 
neuropathological phenotypes will be quantified to assess the degree of Alzheimer’s-like 
pathology in the current study. 
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NFTs and NTs 
Another neuropathological hallmark of AD is intracellular neurofibrillary tangles 
(NFTs) and neuropil threads (NTs), which consist of abnormal phosphorylated Tau 
proteins (Richard E Hartman et al., 2005). Tau proteins stabilize microtubules, a 
component of the cytoskeleton. When tau becomes hyperphosphorylated (multiple 
phosphates attached to it), tau becomes insoluble and lacks affinity for microtubules. This 
causes the hyperphosphorylated tau to detach and self-aggregate and microtubules to 
destabilize, which can lead to the death of the cell. 
 
Cell Loss 
Although neuronal loss does not belong to the diagnostic criteria of AD 
(Duyckaerts, Potier, & Delatour, 2007), it is considered an important pathological 
component of the disease. Several studies have addressed both the presence and absence 
of cellular loss in the hippocampus. Hippocampal cell loss was observed in vitro in both 
human and animal models (Estus et al., 1997; Friedrich et al., 2010; Ji et al., 2002; Loo et 
al., 1993) as well as in vivo in mouse models (Calhoun et al., 1998; Casas et al., 2004; 
LaFerla, Hall, Ngo, & Jay, 1996; Schmitz et al., 2004) in some studies, but not observed 
in other in vivo mouse studies (Irizarry et al., 1997; Jawhar, Trawicka, Jenneckens, Bayer, 
& Wirths, 2012; Takeuchi et al., 2000). This contradicting evidence suggests that 
hippocampal cellular loss in AD is something to be further investigated. 
 
Familial vs. Sporadic AD 
AD can present as early onset familial AD (FAD) or later onset “sporadic” AD. In 
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familial AD (FAD), the less common of the two, autosomal genetic mutations directly 
cause the disease. This form of AD accounts for 1-5% of the total cases of AD (Demattos 
et al., 2000). Most of these cases occur before the age of 60, which is why it is often 
called early-onset FAD. FAD is caused by inheriting abnormal variations of the amyloid 
precursor protein (APP) gene, the presenilin 1 (PSEN1) gene, and/or the presenilin 2 
(PSEN2) gene. 
In the more common sporadic/late-onset form of AD, genes influence the risk of 
developing the disease rather than directly causing the disease. Sporadic AD usually 
occurs after the age of 60, which is why it is often called late-onset sporadic AD. The 
most-studied gene of susceptibility in sporadic AD is the apolipoprotein E (APOE) gene. 
As shown in Table 1, other genes, including α2M, LRP, ACE, and VLDL-R, can also 
influence susceptibility to sporadic AD (Rocchi, Pellegrini, Siciliano, & Murri, 2003).  
 
Table 1. Genes involved in familial (bold) and sporadic AD.  
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Genetic Risk Factors 
APP 
The inheritance of mutated APP is a risk factor for FAD. Certain mutations in 
APP result in the development of higher than normal levels of Aβ, leading to the 
accumulation of Aβ plaques. This eventually causes neuronal dysfunction in the brain. 
The processing of APP to Aβ occurs in normal individuals as well as those with AD, so it 
is presumed that the development of AD is due to a mutation in this gene, which leads to 
a change in either the quantity or quality of Aβ (LaFerla et al., 1996). These mutations 
are a relatively rare cause of AD (Schellenberg, 1995). Since APP is located on 
chromosome 21 and Down syndrome is caused by trisomy 21 (3 copies of chromosome 
21), those with Down syndrome are more likely to developing AD. 
 
Presenilin 1 and 2 
Once APP mutations were found, extensive research suggested that these 
mutations accounted for only a small subset of AD cases. Genetic linkage analysis led to 
the identification of a chromosome 14 early-onset AD locus (Schellenberg, 1995) 
Presenilins are a family of transmembrane proteins that act as a γ-secretase (an enzyme 
that cleaves transmembrane proteins at residues within the transmembrane domain). The 
presenilin 1 (PSEN1) gene and presenilin 2 (PSEN2) gene have been identified as a cause 
of FAD (Schellenberg, 1995). Mutations in these genes are thought to cause up to 80% of 
FAD cases (Rocchi et al., 2003).  
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APOE 
APOE is a gene located on chromosome 19 that has been shown to play a factor in 
the pathogenesis of late-onset AD. APOE has three major alleles: APOE2 (E2), APOE3 
(E3), and APOE4 (E4). These alleles produce the isoproteins apolipoprotein E2 (apoE2), 
apoE3, and apoE4, respectively (Eto et al., 1986). The likelihood of one developing AD 
is highly dependent upon which of these three alleles they carry (Corder et al., 1993). 
ApoE is a ligand for the low-density lipoprotein receptor (LDLR), which is involved in 
maintaining cholesterol and triglyceride homeostasis (Sullivan et al., 1997). A lipoprotein 
is a group of soluble proteins that transports fats or lipids to the blood plasma. A low-
density lipoprotein (LDL) carries cholesterol throughout the body and delivers it to 
different organs and tissues. LDL is also considered the “bad” cholesterol since it 
contributes to plaques. High-density lipoprotein (HDL) picks up excess cholesterol in the 
blood and takes it back to the liver where it is broken down. It is considered as “good” 
cholesterol since it helps remove LDL cholesterol from the arteries.  
After the liver, the brain expresses the highest expression of apoE, particularly in 
areas involved in neural development, regeneration, and remodeling (Grootendorst et al., 
2005; Kim, Basak, & Holtzman, 2009). The liver synthesizes about 70% of apoE in the 
body, and the brain synthesizes about 20% (Sullivan et al., 1997). Similar levels of apoE 
mRNA have been found in the cerebellum, medulla, and cerebral cortex of the rat brain 
(Elshourbagy, Liao, Mahley, & Taylor, 1985). Besides the liver and the brain, apoE is 
also synthesized in the spleen, lungs, adrenal glands, kidneys, and muscles (Blue, 
Williams, Zucker, Khan, & Blum, 1983; Tokuda et al., 2000). Major cell types that 
express apoE in the brain include astrocytes and microglia (Kim et al., 2009). ApoE has 
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shown to play a role in the brain’s response to injury (Poirier, 1996; Tokuda et al., 2000). 
Following injury, astrocytes and macrophages (cells that function in phagocytosis) 
synthesize and release apoE within the lesion to repair the nervous system through 
membrane synthesis (Poirier, 1996; Tokuda et al., 2000).   
Corder et al. (1993) studied the genotype of 42 late-onset families that were 
diagnosed with AD. Each individual has two APOE genes on chromosome 19. One copy 
is inherited from each parent. With increasing numbers of E4 alleles, they found that the 
risk for AD increased from 20% to 90%, and the mean age of onset decreased from 84 to 
68 years. Compared to individuals lacking E4, those with one E4 allele are 2 to 3 times 
more likely to get AD, and those with two E4 alleles are about 12 times more likely to get 
AD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007). The E4 allele is known to 
increase the risk and decrease the age of onset of AD, whereas the E2 allele is known to 
decrease the risk and increase the age of onset of AD. The E4 allele represents a major 
risk for AD in a variety of ethnic groups (Farrer et al., 1997). A pilot study has found a 
protective role in the E4 allele in the cognitive development in children with heavy 
diarrhea in Northeast Brazil (Oriá et al., 2005).  
The E3 allele encodes for the most common isoform and acts as a neutral allele, 
not modifying the risk of developing the disease. From a normal representative United 
States sample with a similar number of young and elderly males and females (n = 1209; 
age range 22-71 years), the major APOE alleles, E2, E3, and E4, occurred at frequencies 
of 7.5, 78.6, and 13.5%, respectively (Ordovas et al., 1987). Other rare isoforms (E1, E5, 
and E7) have been reported (Weisgraber, Rail, Innerarity, & Mahley, 1984; Yamamura, 
Yamamoto, & Sumiyoshi, 1984). The E1 and E5 alleles were found to occur at 
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frequencies of 0.2% each (Ordovas et al., 1987). Hallman et al. (1991) found no evidence 
that the effects of apoE polymorphism on plasma cholesterol levels were significantly 
different among the nine populations studied; Tyrolean, Sudanese, Indian, Chinese, 
Japanese, Hungarian, Icelandic, Finnish, and Malay. The frequencies did vary by 
population though. The Chinese and Japanese appeared to show higher frequencies of ε3 
and lower frequencies of ε4 than did the other populations. The high frequency of ε3 in 
both populations has been reported in previous studies (Asakawa, Takahashi, Rosenblum, 
& Neel, 1985; Eto et al., 1986; Tsuchiya et al., 1985).  
The three alleles differ in their affinity for the LDLR. ApoE3 and apoE4 have a 
100% binding affinity to LDLR (leading to an increase in LDL cholesterol), while apoE2 
only has 1% normal binding affinity (leading to a decrease in LDL cholesterol; Sullivan 
et al., 1997). Despite the lowing binding affinity of apoE2 for the LDLR, individuals 
homozygous for ε2 usually have lower than normal plasma cholesterol levels, except for 
the fraction of homozygotes (5-10%) who develop type III hyperlipoproteinemia 
(Utermann, 1982).  
Schmechel et al. (1993) selected autopsy-confirmed cases of late-onset AD 
without affected family members and without other neurological disease as subjects for 
their study. They found that the average neuritic plaque counts increased with two, as 
opposed to one, copy of E4, and that the number of neuritic plaques was greater in the E4 
than in the E4 homozygotes. To further investigate this trend, Schmechel et al. (1993) 
looked at the impact that E3 and E4 alleles had on Aβ plaques in brain tissue sections. 
They reported that homozygotes for E4 had a 5- to 7-fold greater average area covered by 
strongly Aβ plaques compared to E3 homozygotes. Additionally, they found that there 
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was a significant dose-related increase of vascular amyloid with the number of E4 alleles. 
No vascular amyloid was observed in most of E3/3 cases, some vascular amyloid was 
observed in E3/4 cases, and large amounts were reported for E4/4 cases (Schmechel et al., 
1993).  
Previous research using in vitro models report that E4 enhances Aβ production 
whereas E3 does so to a lesser extent (Mahley, Weisgraber, & Huang, 2006; Ye et al., 
2005). Ye et al. (2005) applies these findings to some in vivo findings to explain why E4 
is associated with greater Aβ deposition than E3 in AD brains and in transgenic mice 
expressing mutant APP. Various mouse models suggest how apoE4 can lead to the 
development of Aβ deposits (Bales et al., 1999; Ye et al., 2005). As described by Games 
et al. (1995), the development of Aβ plaques is derived from an accumulation of these Aβ 
deposits, supporting the hypothesis that apoE4 mice will have more AD-like pathology 
than apoE3 mice. 
 
Others 
As mentioned earlier, other genes involved in AD include α2M, LRP, ACE, and 
VLDL-R (Rocchi et al., 2003). Α2-Macroglobulin (α2M) is a serine protease inhibitor, or 
a protein that inhibits the breakdown of other proteins, that is expressed in the brain and 
found in neuritic plaques (Dodel et al., 2000). The α2M gene is located on chromosome 
12p. A genetic linkage was detected in late-onset families for a susceptibility gene on 
chromosome 12 (Pericak-vance et al., 1997), which is why α2M became a candidate as a 
disease locus for FAD. α2M plays a role in mediating the clearance and degradation of 
Aβ (Blacker et al., 1998). Blacker et al. (1998) reported an association between a deletion 
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in exon 18 of α2M and AD in a sample of affected and unaffected siblings segregating 
AD. His study confirmed the risk of AD (OR=3.55) comparable to that of ε4 (OR=3.54). 
However, studies using worldwide populations as samples failed to confirm such an 
association (Dow et al., 1999; Rogaeva et al., 1999). For that reason, the possibility exists 
that this α2M deletion could be a risk factor for FAD only (Rocchi et al., 2003). 
 The LRP gene (low density lipoprotein receptor-related protein) is another 
candidate for a potential association with AD. LRP is the main apoE receptor expressed 
in neurons (Rebeck, Reiter, Strickland, Hyman, & Cross, 1993), is responsible for the 
endocytosis (the process of cells absorbing molecules by engulfing them) of secreted 
APP (Kounnas et al., 1995), and is detected in senile plaques (general term for Aβ 
plaques in the elder population), dystrophic neurites and reactive astrocytes in the AD 
brain (Rebeck, Harr, Strickland, & Hyman, 1995). Multiple studies have shown that 
certain polymorphisms in LRP may play as a minor risk factor for sporadic AD (Kamboh, 
Ferrell, & DeKosky, 1998; Kang et al., 1997; Lendon et al., 1997). 
 The ACE gene (angiotensin converting enzyme) encodes for an enzyme that 
catalyzes the conversion of angiotensin I to angiotensin II (Rocchi et al., 2003), a protein 
that causes vasoconstriction. A polymorphism in ACE has been found to be associated 
with AD susceptibility (Kehoe et al., 1999). Subsequent studies confirmed that certain 
polymorphisms in ACE lead to an increased risk in late-onset AD (Alvarez et al., 1999) 
including in Chinese (Cheng, Hong, Liu, Liu, & Tsai, 2002) and Japanese (Hu et al., 
1999) populations.  
 The VLDL-R gene (very low density lipoprotein receptor) is located on 
chromosome 9. VLDL-R has shown to be found on microglia, particularly those 
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associated with senile plaques (Christie, Chung, Rebeck, Strickland, & Hyman, 1996). A 
number of genetic studies have investigated the effect that a polymorphic trinucleotide 
(CGG) repeat sequence of VLDL-R, with alleles ranging from four to nine repeats, will 
have on the risk for AD. A study investigating the Japanese population homozygous for 
the five repeats allele leads to an increased risk for AD (Okuizumi et al., 1995). Contrary 
to that study, there were no significant differences between AD cases and controls in 
allele frequencies of the CGG repeat polymorphism in the Caucasian population 
(Okuizumi et al., 1996). A case study was then done investigating these effects in late-
onset AD patients from Northern Ireland (McIlroy et al., 1999). Findings suggested 
carriers of 9,9 genotype of VLDL-R are at increased risk of AD in Northern Ireland. 
Although the genetic studies from distinct populations on the CGG repeat polymorphism 
in the 5’-untranslated region of VLDL-R obtained inconsistent results, the possibility of 
VLDL-R acting as a susceptibility gene for AD exists.  
 
Animal Models 
Natural AD Development 
Before the development of molecular genetics, the study of genes and pathology 
was limited to inherited characteristics or spontaneous mutations. Selective breeding was 
a common method that was used. Natural AD development has been studied in chickens, 
dogs, non-human primates, dolphins, bears, guinea pigs, and rabbits because of their 
highly homologous Aβ sequence to that of humans. Rats and mice, on the other hand, 
have a distinct Aβ sequence from humans that does not naturally aggregate into a β-sheet 
conformation. Chickens, dogs, non-human primates, dolphins, and bears have shown age-
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related human-like AD neuropathology, whereas, despite their homologous Aβ sequence 
to that of humans, guinea pigs, and rabbits did not. 
Carradeguas et al. (2005) revealed that the sequence of chicken APP is very 
similar to the human sequence of APP. They also reported that the chick embryo 
processes APP by both amyloidogenic (cleavage by β- and γ-secretases, leading to the 
formation of Aβ plaques) and non-amyloidogenic (cleavage by α-secretase, preventing 
the formation of Aβ plaques) pathways. In addition to the chicken Aβ sequence’s 
similarity to that of humans, they also reported that Aβ42 was the major Aβ peptide 
produced during chick embryogenesis (the formation and development of an embryo), 
suggesting that the chick embryo may be appropriate for studying the mechanisms of Aβ 
production.  
Age-related Aβ deposition was reported in the prefrontal, occipital, parietal, and 
entorhinal cortices of 40 beagle dogs ranging from 2 to 18 years of age (Head, McCleary, 
Hahn, Milgram, & Cotman, 2000). Head et al. (2000) also found that the earliest and 
most consistent site of Aβ deposition with age was in the prefrontal cortex, similar to 
what is seen in the aging human. It has also been reported that the extent of the Aβ is 
correlated with learning and memory impairments in aging dogs (Cummings, Head, 
Afagh, Milgram, & Cotman, 1996a; Cummings, Head, Ruehl, Milgram, & Cotman, 
1996b).  
Natural models of non-human primates, dolphins, and bears have been studied as 
well (Cork et al., 1988; Sarasa & Pesini, 2009). Unlike wild-type mice, many non-human 
primates naturally develop Aβ plaques (Lemere et al., 2008). Lemere et al. (2008) found 
age-related plaque deposition in tamarins older than 12 years of age. Also, tissue samples 
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from stranded dolphins were found to have extensive positive Aβ-immunolabeled 
deposits throughout the brain, including the cerebellum and medulla oblongata where 
such deposits have only been reported in more severe cases of AD (Luo et al., 2001). The 
Aβ42 peptide in three dolphin species was found to be 100% identical to the human 
peptide (Sarasa & Pesini, 2009). Furthermore, two different types of bears have also 
shown age-related human-like AD pathology (Cork et al., 1988). A 20-30 year old 
Asiatic brown bear and polar bear displayed NFTs and numerous senile plaques, 
respectively (Cork et al., 1988). 
Although the Aβ sequence in guinea pigs and rabbits happen to be identical to 
that of human (Johnstone, Chaney, & Norris, 1991), Sarasa and Pesini (2009) reported 
that these animals did not present AD pathology spontaneously. Guinea pigs did not 
develop the pathological features of AD, such as senile plaques and neurofibrillary 
tangles. Although rabbits did not present AD pathology spontaneously, Wu et al. (2003) 
reported that increased dietary cholesterol levels in rabbits led to increased Aβ and apoE 
concentrations in the temporal and frontal cortices, regions where amyloid deposits have 
been displayed in the pathology of AD.  
Perhaps other factors, aside from the similar Aβ sequence to that of humans, may 
describe the possible mechanism for why guinea pigs and rabbits do not develop age-
dependent AD-like neuropathology. The natural development of amyloid deposits may be 
closely linked with the concentrations of β- and γ- secretase in the brain or a specific diet 
that these animals generally have. 
 
 
 20 
Non-Transgenic Models 
Before transgenic animals models became popular, non-transgenic animal models 
were used. In these cases, the genetic material of the animal was not altered. Examples 
consisted of injecting the Aβ40 peptide into rat brains via intrahippocampal injection 
(Stéphan, Laroche, & Davis, 2001) or the Aβ42 peptide via intracerebroventricular 
infusion (Lecanu, Greeson, & Papadopoulos, 2006; Nakamura, Murayama, Noshita, 
Annoura, & Ohno, 2001). The overall goal in these studies was to inject a form of 
amyloid peptide into the rat brain so that the animal would develop the pathological 
features representative of AD. Alternative non-transgenic animal models include 
streptozotocin injections (Y. Chen et al., 2013), okadaic acid-induced tau protein 
hyperphosphorylation (Y.-W. Lim et al., 2010), and aluminum salt administration (Aly, 
Metwally, & Ahmed, 2011). Also, a study from our group, in which a controlled cortical 
impact (CCI) injury was administered to the parietal cortex of male rats at postnatal day 
17, reported higher levels of endogenous rodent Aβ in several brain regions (Pop et al., 
2012). These findings suggest that juvenile traumatic brain injury (jTBI) animals may be 
used an effective non-transgenic model for AD.  
 
Transgenic/Knockout Models 
The term “transgenic” refers to the artificial introduction of genetic material from 
one organism to another. The first genetically modified animal was created in 1974, by 
Rudolf Jaenisch (Jaenisch & Mintz, 1974). He had inserted a DNA virus into an early-
stage mouse embryo and showed that that inserted gene was present in every cell, but the 
transgene (the gene that has been transferred from one organism to another) was not 
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passed to their offspring. In 1981, transgenic mouse models had successfully shown 
transmission of genetic material to subsequent generations (Brinster et al., 1981; 
Constantini & Lacy, 1981; Gordon & Ruddle, 1981). Gordon and Ruddle (1981) used 
one of today’s most common methods for generating transgenic mice, DNA 
microinjection. This method consists of injecting a single gene or a combination of genes 
from one organism to another. This insertion of DNA is a random process, and there is no 
way to ensure that the DNA will insert itself into a site on the host DNA that will permit 
its expression. 
Another method of generating transgenic mice is by way of embryonic stem cell-
mediated gene transfer. The first recorded KO mouse was in 1989 (Capecchi, 1989). This 
method consists of inserting mutant embryonic stem (ES) cells, which are 
undifferentiated cells that still have the potential to differentiate into any type of cell 
(somatic and germ cells), into blastocysts in an embryo. This allows for the insertion of a 
certain gene in a specific location of the researcher’s choice.  
 
APP Models 
Mutations  
Prior to the development of PDAPP mice, animals transgenic for APP had failed 
to show extensive AD-like neuropathology (Lamb et al., 1993; Quon et al., 1991). Quon 
et al. (1991) generated transgenic mice that expressed APP-751, an isoform of APP. 
These mice exhibited poorly resolved extracellular Aβ deposits in the hippocampus and 
cortex. Lamb et al. (1993) introduced APP into mouse embryonic stem cells, which 
showed no evidence of AD-type pathology. 
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Once FAD-associated mutations in APP had been discovered, the focus of making 
AD transgenic mouse models turned to including the overexpression of transgenes 
containing FAD mutations (Elder et al., 2010). Games et al. (1995) created the first 
successful AD transgenic mouse model that contained an FAD-associated mutation. The 
resulting high level of human mutant APP in the brains of these mice resembled that of 
early-onset FAD. This model consists of a human APP minigene, or a segment of APP 
that codes for a portion of the APP protein, with a mutation that causes FAD (APPV717F). 
The nomenclature of the mutation suggests that the valine amino acid (V) gets replaced 
with the phenylalanine amino acid (F) at residue 717 along the APP peptide. The FAD 
mutation at residue 717 shifts the production of Aβ from the 40-amino-acid form to the 
longer and more amyloidogenic 42-residue peptide known to predominate in plaques ( a. 
E. Roher et al., 1996; Suzuki et al., 1994). It is also highly expressed in the central 
nervous system (Elder et al., 2010). This line became known as PDAPP (Platelet-Derived 
growth factor promoter driving Amyloid Precursor Protein; Elder et al., 2010). In the 
PDAPP transgenic mouse model, mice express high levels of human mutant APP, 
causing neuropathology resembling that of early-onset FAD. This causes the mice to 
progressively develop many of the pathological hallmarks of AD (Games et al., 1995), 
such as age-dependent amyloid deposition in the brain, along with thioflavin-S-positive 
plaques (Elder et al., 2010). PDAPP mice also developed age-related learning defects 
(Richard E Hartman et al., 2005) and synapse loss (Elder et al., 2010). The first PDAPP 
line generated showed no obvious pathology before about 6 months of age (Games et al., 
1995). At about 6-9 months of age, these transgenic mice showed Aβ deposits in the 
hippocampus, corpus callosum, and cerebral cortex. 
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Another line of transgenic mouse created from FAD-associated mutations is the 
Tg2576 mouse (Elder et al., 2010). These mice, also known as APPsw, overexpress a 
human APP transgene containing the Swedish FAD mutation (K670N/M67IL). This is a 
double mutation where lysine (K) is replaced with asparagine (N) at residue 670, and 
methionine (M) is replaced with leucine (L) at residue 671. These mice exhibited learning 
and memory impairments by 9 to 10 months of age with a resulting a five-fold increase in 
Aβ40 and a 14-fold increase in Aβ42 accompanying these behavioral deficits (Hsiao et al., 
1996). Considering how Aβ42 aggregates more rapidly and is more toxic to the neuron 
compared to Aβ40 (Yan & Wang, 2006), these findings suggest the harmful effects of this 
mutation. PDAPP mice (Fryer et al., 2003) generally have a lower ratio of Aβ40:Aβ42 
compared to Tg2576 mice (Hsiao et al., 1996; Johnson-Wood et al., 1997). Other 
transgenic AD mouse lines with FAD-type mutations include APP23, TgCRND8, APP-
Dutch, PS1M146V, PSAPP, and 3xTg (Elder et al., 2010; Table 2). 
 
  
 24 
Table 2. Selected examples of AD mouse models.  
 
 
APOE Models 
Knockout 
KO mice are defined as mice whose DNA has been genetically engineered so that 
it does not express particular proteins. In the current study, that particular protein is apoE. 
ApoE KO mouse models have been used to investigate the role of apoE in the nervous 
system. Fagan et al. (1998) found no significant defects in the septo-hippocampal 
cholinergic system (plays a role in spatial working memory) in aged apoE KO mice (up 
to 24 months of age). Hartman et al. (2001) found that mice lacking apoE were 
significantly more active than wild-type mice. Also, Shibata et al. (2000) found that, 
compared to adult wild-type mice, Aβ clearance was significantly reduced in young and 
old apoE KO mice. 
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Human APOE 
Other studies investigated the role of human APOE in the AD brain by using 
human apoE KI mouse models. Sullivan et al. (1997) used a gene replacement strategy to 
generate mice that express human E3 in place of murine APOE. Although murine APOE 
is about 70% identical to human APOE at the amino acid level, there are inherent 
functional differences between murine and human APOE isoforms on plasma lipoprotein 
metabolism in vivo (Sullivan et al., 1997). He found that after the 3/3 (E3 KI) and WT 
mice were fed a high fat/high cholesterol diet, the 3/3 mice responded with an increase in 
cholesterol 5 times to that of the WT mice. After 12 weeks of being on the diet, the 3/3 
mice also developed 13-fold larger atherosclerotic plaques in the aortic sinus area than 
the WT mice. In contrast to murine APOE, human APOE isoforms have been known to 
suppress early Aβ deposition and Aβ levels in 9-month-old PDAPP mice (D M Holtzman 
et al., 2000; David M Holtzman et al., 1999). 
Yao et al. (2004) compared Aβ accumulation among human E3 KI, human E4 KI, 
and murine APOE KO mice. They found that E4 carriers had higher levels of Aβ than 
either E3 or APOE KO mice. Aged male E4 mice appeared to have the highest average 
values for Aβ40, Aβ42, and total Aβ (Yao et al., 2004). Grootendorst et al. (2005) was the 
first study to investigate and compare the behavioral phenotype of KI human E3 and E4. 
He found that spatial memory deficits occurred particularly in human E4 mice, especially 
female.  
 
APP x APOE Models 
Once APOE KO mouse models had led to a more clear understanding of the apoE 
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protein, APOE KO mice were crossed with PDAPP mice. Bales et al. (1999) found that 
the amount of Aβ immunoreactivity in the hippocampus of transgenic mice 
overexpressing the V717F human APP with no, one, or two APOE alleles was 
dramatically reduced in an APOE dose-dependent manner (APOE+/+ > APOE+/- >> 
APOE-/-). Bales et al. (2009) further investigated the role of human APOE on Aβ 
deposition by crossing PDAPP mice lacking murine APOE to targeted replacement mice 
expressing human E4 (PDAPP/TRE4). They found that the brain levels of Aβ42 in 
PDAPP/TRE4 mice were significantly elevated in young mice.  
Hartman et al. (2002) investigated these effects in a PDAPP x APOE model 
having undergone traumatic brain injury (TBI). They found that TBI accelerated Aβ 
deposition, such that PDAPP mice expressing E4 displayed Aβ deposition by 12-13 
months of age in the presence of TBI compared to about 15 months of age in the absence 
of TBI. They also found a greater and earlier amyloid deposition in PDAPP:E4 mice than 
in PDAPP:E3 mice in the presence of TBI.  
 
Humans with AD 
Studies on humans with AD have assessed the differences in neuropathological 
and behavioral deficits between those who are carriers of the E4 allele versus those who 
are carriers of the E3 allele. In a study assessing 194 AD cases and 3,984 cognitively 
normal controls, findings indicated E4 was significantly associated with an increased risk 
of AD compared to E3 (Lindsay, J., Laurin, D., Verreault, R., Hebert, R., Helliwell, B., 
Hill, G. B., McDowell, 2002). Specifically, those who had at least one E4 allele had 3.28 
times the risk of AD compared to those who were homozygous for the E3 allele.  
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In terms of neuropathological deficits, the apoE isoform 4, which is the protein 
encoded by the E4 allele, has a higher avidity in vitro for β-amyloid than the apoE 
isoform 3 (Corder et al., 1993). This study found that E4 increases the rate and extent of 
amyloid deposition compared to the E3 allele.  Another study (Schmechel et al., 1993), 
found that late-onset AD patients with one or two E4 alleles have a distinct 
neuropathological phenotype compared with patients homozygous for the E3 allele. 
Specifically, AD patients homozygous for the E4 allele had abundant immunoreactive 
plaques whereas AD patients homozygous for the E3 allele only had slight 
immunoreactive plaques. These differences were so evident that they were often observed 
without a microscope. AD patients homozygous for the E4 allele also had more neuritic 
plaques and NFTs in the CA1 subfield of the hippocampus and cortical regions compared 
to those homozygous for the E3 allele. In another study, E4:E3 AD patients also had 
lower cortical thickness values compared to those homozygous for the E3 allele in 
regions associated with early pathological changes in AD (CA1 subfield of the 
hippocampus and parietal regions). 
In terms of behavioral changes, Bookheimer et al. 2000 found that AD patients 
who were carriers of the E4 allele had lower scores on a delayed-recall test, although not 
significantly lower, than did carriers of the E3 allele. They also found significant 
increases in the functional magnetic resonance imaging (fMRI) signal intensity during 
learning and recall periods as compared with resting periods. This intensity was greater 
among the carriers of the E4 allele compared to carriers of the E3 allele, which was later 
correlated with degree of decline in memory in a longitudinal assessment after two years. 
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These findings suggested that subjects at genetic risk for AD used greater cognitive effort 
to achieve the same level of performance as subjects who were not at genetic risk. 
 
Thesis 
The double-transgenic mice used for the current study were obtained from the Eli 
Lilly Corporation in 2009, where they crossbred PDAPP transgenic mice with apoE KO 
mice. This KO technology consisted of removing the murine APOE from their genomes 
and, via KI technology, replacing it with a human variation of E3 or E4 in the precise 
location within the mouse genome that the murine APOE was removed from. Given the 
similarities in behavior and neuropathology between humans with AD and transgenic 
mouse models for AD, transgenic mouse models for AD have frequently been used to 
gain a better understanding of the disease and to characterize the neuropathological 
mechanisms. 
 
Hypothesis One 
The first hypothesis states that PDAPP:E4 mice will show more Alzheimer’s-like 
pathology in the hippocampus and dorsal cortex than the PDAPP:E3 mice. The 
hippocampus and cingulate cortex showed dramatic age-related increase in Aβ levels in 
PDAPP mice (Johnson-Wood et al., 1997) and in mice that co-express five FAD 
mutations (Oakley et al., 2006). The hippocampus also showed significantly more Aβ 
load in old PDAPP mice compared to young or middle-aged PDAPP mice (Games et al., 
1995) and in PDAPP mice of all ages compared to controls (Demattos et al., 2000). 
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A study was done to assess the amount of amyloid deposition, which is a main 
component of Aβ plaques, in three different mouse genotypes of one particular mouse 
model overexpressing APPV717F (PDAPP; Bales et al., 1999). Mice that were 
homozygous (carrying two identical alleles of a particular gene) for the APPV717F 
transgene were crossed to an APOE KO mouse. The resulting hemizygous progeny were 
subsequently bred, and the following genotypes were selected for the study: APPV717F+/-
:APOE-/- (1 copy of the human APPV717F; 0 copies of murine APOE), APPV717F+/-:APOE+/-
(1 copy of the human APPV717F; 1 copy of murine APOE), and APPV717F+/-:APOE+/+(1 
copy of the human APPV717F; 2 copies of murine APOE). The results suggested that in the 
case of the APPV717F+/- APOE-/- mice, where the mice were APOE-deficient, no amyloid 
deposits were formed at 9, 15, or 21-22 months. When mouse APOE was present (as with 
the APPV717F+/-:APOE+/- and APPV717F+/-:APOE+/+ mice), the researchers found an age-
related increase of amyloid deposits in the hippocampus and the cortex. These results 
suggest that amyloid deposits develop in cases where APOE is present, but not when 
APOE is absent. Although these mice expressed mouse (murine) APOE rather than 
human APOE, the findings emphasize the critical role that APOE plays in amyloid 
deposition, especially when there is an overexpression of mutant APP. 
Johnson-Wood et al. (1997) measured the total Aβ and APP measurements in 
PDAPP mice from 4 to 18 months of age. A total Aβ sandwich ELISA (enzyme-linked 
immunosorbent assay), a test using antibodies and color change to detect a sample 
antigen by “sandwiching” the antigen in between the two antibodies, was conducted. This 
test used antibodies 266 and 3D6, which are specific to certain amino acid epitopes 
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within the Aβ peptide. The Aβ levels appeared to increase significantly by age in the 
hippocampus (Figure 2).  
 
 
Figure 2. The age-dependent changes in brain Aβ levels in the PDAPP transgenic mice 
in the hippocampus (white circle), cortex (white diamond), and cerebellum (black square). 
PDAPP mice were sacrificed at the ages indicated. The Aβ levels increased significantly 
by age in the hippocampus compared to the other cortex and cerebellum (Johnson-Wood 
et al., 1997). 
 
 
There was also an age-related increase in Aβ in the hippocampus of PDAPP mice due to 
Aβ42. Aβ42 comprised of 27% of the 17 pmol/g of Aβ present in the brains of young 
animals and increased to 89% of the 694 pmol/g in the 12-month-old animals. Between 
12 and 16 months of age, an even more dramatic increase in deposition of Aβ occurred in 
the hippocampus and frontal region of the cortex. By 18 months, Aβ42 levels in the 
PDAPP mice were comparable to the higher Aβ levels observed in humans with AD 
(Gravina et al., 1995). Initially, before amyloidotic deposition, there were 38.1 pmol/g of 
Aβ in the hippocampus of these young animals. The model used by Johnson-Wood et al. 
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(1997) is an accurate representation of human AD pathology such that the majority of 
depositing Aβs in these mice were in the longer Aβ42 form, and studies of human AD 
have shown that the predominant and initially depositing Aβs are the longer form. 
 APP/PS1 double transgenic mice overproduce Aβ42 and exhibit plaque pathology, 
but transgenic mice develop plaques slowly. The majority of AD transgenic mouse 
models take about 6-12 months, or longer, to form amyloid plaques (Oakley et al., 2006). 
To accelerate plaque development, Oakley et al. (2006) investigated APP/PS1 double 
transgenic mice that co-express five FAD mutations (5XFAD mice) to investigate the 
effects of high Aβ42 levels. The five FAD mutations were APP K670N/M671L (Tg2576 
mice previously described), APP I716V (isoleucine is replaced with valine at residue 716 
on the APP peptide), APP V717I (valine is replaced with isoleucine at residue 717 on the 
APP peptide), PS1 M146L (methionine is replaced with leucine at residue 146 on the PS1 
peptide), and PS1 L286V (leucine is replaced with valine at residue 286 on the PS1 
peptide). These mutations were introduced into the cDNA (complimentary DNA) by site-
directed mutagenesis. They found that intraneuronal Aβ42 accumulated at 1.5 months of 
age, before the first appearance of Aβ deposits at 2 months. There was a rapid increase of 
cerebral Aβ42 levels in 5XFAD mice (Oakley et al., 2006). At young ages, these mice 
generated Aβ42 levels almost exclusively (Figure 3). Aβ40 levels began to rise at older 
ages, although always lower than Aβ42 levels (Figure 3).  
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Figure 3. The rapid increase of cerebral Aβ42 levels in 5XFAD lines from 1.5 to 16-
month-old 5XFAD mice (A. Tg6799; B. Tg7092; C. Tg7031; D. Tg2576). (Oakley et al., 
2006). 
 
In a study of confirmed cases of AD, in which autopsies were performed within 8 
hours from death, those who were homozygous for the E4 allele had increased neuritic 
plaques compared with patients with no E4 alleles. This suggests a positive correlation 
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between plaque density and E4 allele dose (Tiraboschi et al., 2004). It is believed that the 
physical interaction of APOE with Aβ plays an important role in AD pathogenesis. 
It is the specific effect that E3 and -4 have on the human Alzheimer’s brain that 
are of interest in the current study. The binding affinity of E4 with Aβ is high and has 
significantly different binding characteristics compared to that of E3 (Schmechel et al., 
1993). Schmechel et al. (1993) looked at the relationship that E3 and -4, the two most 
common alleles of the APOE gene, have on Aβ deposition in late-onset AD, since E4 is a 
susceptibility gene for late-onset AD. They found that patients with sporadic late-onset 
AD who have one or two copies of E4 have a distinctive neuropathological phenotype of 
greatly increased vascular and plaque amyloid deposits compared to patients homozygous 
for E3. 
As mentioned earlier, in selected autopsy-confirmed cases of late-onset AD, 
Schmechel et al. (1993) found more Alzheimer’s-like pathology (neuritic plaques, Aβ 
plaques, and vascular amyloid) in E4 homozygotes than E3 homozygotes. Several other 
studies, as mentioned earlier, have reported that E4 enhances Aβ production while E3 
does so to a lesser extent (Kelly R. Bales et al., 1999; Mahley et al., 2006; Ye et al., 
2005). In one mouse model, highly relevant to the current study, Bales et al. (2009) 
measured the levels of APOE protein and Aβ peptides in mice at different ages. The 
mouse model consisted of crossing PDAPP mice lacking mouse APOE to targeted 
replacement mice expressing human APOE. Findings suggested that there was an age-
dependent increase in both Aβ40 and Aβ42, regardless of APOE isoform analyzed, which 
was more pronounced in the PDAPP/TRE4 mice. This study also did not administer any 
behavioral tests on their mice, something that our study will be addressing. By running 
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behavioral tests in our study, we are able to analyze any correlates between the 
behavioral deficits and neuropathology seen in their brains. Having a clear understanding 
of the impact that specific isoforms of APOE play in the development of AD can lead to 
the development of preventive techniques as well as accurate prognoses of AD patients. 
 
Hypothesis Two 
The second hypothesis states that the PDAPP:E4 mice will have fewer cells in the 
hippocampus and cortex than the PDAPP:E3 mice. The hippocampus, specifically the 
CA1 hippocampal subfield (Figure 4), is known to have substantial neuronal loss in AD 
patients (Mann, 1996; West, Coleman, Flood, & Troncoso, 1994) as well as in APP23 
transgenic mice (Calhoun et al., 1998).  
 
 
Figure 4. A sagittal view of a wild-type mouse brain. The CA1 hippocampal subfield is 
known to have substantial neuronal loss in AD patients (Mann, 1996; West et al., 1994) 
as well as in APP23 transgenic mice (Calhoun et al., 1998).   
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Several studies of various transgenic mouse models of AD have also reported a lack of 
cell loss in the CA1 hippocampal subfield (Irizarry et al., 1997; Jawhar et al., 2012; 
Takeuchi et al., 2000). Although studies have shown both the presence and absence of 
cell loss in various transgenic mouse strains, the phenomenon has yet to be studied in 
PDAPP mice that also express human E3 or E4.  
In one study (Friedrich et al., 2010), Aβ aggregation was induced in vitro by 
adding dissolved Aβ40 to cultures of several cell types (human embryonic kidney cells, 
neuroblastoma cells, laryngeal carcinoma cells, monocytic cells, simian kidney cells, and 
a murine macrophage line). These cells lines are relevant to AD in that they all share the 
ability to enable Aβ plaque formation. They found that plaque biogenesis involves Aβ 
accumulation within intracellular vesicles, and the fibrils formed by Aβ in these 
conditions impair the ordered vesicular formation by growing out and penetrating the 
vesicular membrane. These events lead to the death of the affected cells and the 
extracellular accumulation of previously intracellular amyloid structures (Friedrich et al., 
2010). The cell death reported in this cell-culture system is associated with plaque 
biogenesis, not necessarily with the massive neuronal loss in AD patients. Duyckaerts et 
al. (2007) found that transgenic mouse brains can have a lot of Aβ plaque despite very 
little neuronal death, supporting the notion that cell death is not related to the massive 
neuronal loss in AD patients. 
In another in vitro study, the isoform-specific effects of APOE on the response of 
Neuro-2a cells to the Aβ peptides were assessed. Neuro-2a is a mouse neural crest-
derived cell line, which is beneficial in the fact that they differentiate into neurons within 
a few days. This allows for an efficient way of studying neurons. ApoE3- and E4-
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transfected Neuro-2a cells were incubated with 20 µM Aβ42 for 18 hours at 37ºC, and cell 
survival was assessed. Transfection is a method of introducing nucleic acids into cells. 
Findings suggest that Aβ42 caused significantly greater cell death in E4-secreting than in 
E3-secreting or control cells (Ji et al., 2002). This provides evidence for the second 
hypothesis that E4 leads to more cell death than E3 in the presence of Aβ. 
Estus et al. (1997) found that treatment of cultured rat cortical neurons with Aβ40 
results in a widespread of apoptotic neuronal death. Apoptosis refers to a regulated self-
destruction of cells whereas necrosis refers to cell death due to disease, injury, or failure 
of the blood supply. Finally, Loo et al. (1993) studied cultured cortical and hippocampal 
neurons from mouse embryos treated with Aβ42. They reported that these neurons 
exhibited classical morphological and biochemical characteristics of apoptosis, which 
they believe may play a role in the neuronal loss associated with AD. The concentration 
Aβs used in these in vitro studies ranged from 5-40 µM. 
In an in vivo study, LaFerla et al. (1996) found that their transgenic mouse model 
(overexpression of the murine homologue of the Aβ peptide), consisting of intracellular 
expression of Aβ specifically in neurons, led to the death of neurons as well as the 
functional impairment of neighboring neurons. They found that the hippocampus of the 
Aβ transgenic mice, among other areas in the cerebral cortex, was an area of apoptotic 
cells. The observation that Aβ expression induces cell death through the apoptotic 
pathway in vivo may prove relevant for therapeutic approaches to the treatment of AD.  
 Further transgenic studies have addressed the cell loss associated with APP and 
PS mutations. In Schmitz et al. (2004), neuronal loss was observed in transgenic mice 
expressing human mutant APP (APP751) and human mutant presenilin-1 (PS-1 M146L). 
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This specific mutation in APP consists of the KM670/671NL and V717I mutations. They 
found no hippocampal granule cell loss (cells located in the dentate gyrus of the 
hippocampus) at 17 months of age in the APP/PS-1 double transgenic mice as compared 
to age-matched PS-1 single-transgenic mice and wild-type controls. The neuron loss was 
observed at sites of Aβ aggregation. The amount of extracellular Aβ aggregates in these 
APP/PS-1 double transgenic mice increased as they aged, and they found a clear age-
related loss of neurons in the pyramidal cell layer of the hippocampus (Schmitz et al., 
2004). Specifically, they found a substantial loss of pyramidal neurons in the 
hippocampus of 17-month-old APP/PS-1 double transgenic mice compared to 4.5-month-
old APP/PS-1 double transgenic mice and wild-type controls. The neuronal loss was also 
observed in areas of the parenchyma, the functional tissue in the brain, distant from 
plaques. Also, they found no correlation between the number of pyramidal cells and 
plaque load, which fell in line with a study reporting little or no correlation between the 
level of neuron loss and the amount of extracellular Aβ in human AD (Gomez-isla et al., 
1997). This suggests the possible involvement of more than one mechanism of 
hippocampal neuron loss in this double-transgenic mouse model of AD. Perhaps part of 
the hippocampal neuron loss may be due to the high levels of intra-neuronal Aβ 
independent of extracellular Aβ aggregates.  
Another study had reported significant neuron loss in the hippocampal CA1 
region in APP23 transgenic mice compared with controls, which was correlated with 
CA1 plaque load in the transgenic mice within the hippocampus (Calhoun et al., 1998). 
In this study, the CA1 neuron loss in the APP23 transgenic mice was 14% and had 
reached 25% in mice with high plaque load (Calhoun et al., 1998). Other studies have 
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failed to find CA1 hippocampal neuron loss in PDAPP transgenic mice through 18 
months of age (Irizarry et al., 1997), PSAPP mice doubly expressing AD-associated 
mutant presenilin-1 (PS-1) and APPsw (Takeuchi et al., 2000), and 5XFAD mice (Jawhar 
et al., 2012). Jawhar et al. (2012) found significant pyramidal neuron loss in layer 5 of the 
cortex, leaving the hippocampus of the 5XFAD mice completely unaffected (Oakley et 
al., 2006). 
A more severe hippocampal neuronal loss is seen a APP/PS1K1 mouse model 
(Casas et al., 2004). The transgenic mouse model carries M233T/L235P (a double 
mutation where methionine is replaced with threonine at residue 233 and leucine is 
replaced with proline at residue 235) KI mutations in presenilin-1 and overexpresses 
mutated human APP. At 10 months of age, these transgenic mice showed an extensive 
neuron loss (>50%) in the hippocampus. The neuron loss was correlated with the 
accumulation of intraneuronal Aβ and thioflavin-S-positive intracellular material. 
As addressed by our first hypothesis, E4 leads to greater Aβ production than does 
E3 in transgenic mice and humans (Kelly R. Bales et al., 1999, 2009; Mahley et al., 2006; 
Schmechel et al., 1993; Tiraboschi et al., 2004; Ye et al., 2005). Previous studies have 
also shown that Aβ aggregation induces neuronal cell death (Estus et al., 1997; LaFerla et 
al., 1996; Loo et al., 1993). Intuitively, one would induce that E4 must lead to more 
neuronal cellular death than E3, but research has shown no correlation between Aβ 
deposition and neuronal loss (Gomez-isla et al., 1997; Schmitz et al., 2004). Although, 
the pyramidal neuron loss in cortical layer 5 (Oakley et al., 2006) occurred in brain 
regions with the highest levels of both intraneuronal Aβ accumulation and amyloid 
plaque burden.  In fact, the actual link between amyloid plaques and neuronal loss has yet 
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to be established (Schmitz et al., 2004). The current study investigates neuronal loss in 
the PDAPP x apoe3 vs. apoe4 model. 
 
Hypothesis Three 
The third hypothesis states that the Alzheimer’s-like pathology will be positively 
correlated with the behavioral deficits displayed in the mice. In humans with AD, 
cognitive and behavioral disturbances caused by the disease do not become evident until 
years after significant neuropathology, which includes a large amount of plaques 
accumulating and the occurrence of cell death (Morris & Price, 2001). Hartman et al. 
(2005) reported that PDAPP mice had substantial learning impairments from early ages, 
as well as an age-dependent decline in learning ability. Whereas both non-transgenic and 
PDAPP mice showed evidence of decreased performance with age in the spatial learning 
task, the performance of PDAPP mice declined much more severely. This suggests that 
age-related Aβ buildup may have negative consequences for spatial learning. They then 
treated the non-transgenic and PDAPP mice with anti-Aβ antibody 10D5, a reagent 
specific for human Aβ, to determine whether this learning impairment was due to Aβ 
accumulation. They found that aged PDAPP mice exhibited significant improvements in 
the spatial learning task, suggesting that Aβ contributed to the age-dependent learning 
deficits displayed in PDAPP mice, providing support for our third hypothesis. Similarly, 
in another study in which spatial learning performance was tested in PDAPP and non-
transgenic mice, a significant negative correlation between spatial learning capacity and 
plaque burden existed for middle-aged and old PDAPP mice (G. Chen et al., 2000). They 
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also found that PDAPP mice had a significant age-related increase of plaque burden in 
the hippocampus. 
The overall goal of the current study is to determine the roles that E3 and -4 play 
in a PDAPP x APOE double transgenic mouse model. Understanding this role will 
provide further insights into its pathophysiological role in AD. Also, these further 
insights will lead to the development of more effective treatments and therapeutics for the 
disease. 
 
Successful Completion of Aims 
Achievement of the first two aims will allow us to determine the effects of apoE 
isoforms and overexpression of human mutant APP on AD-like pathology and cell count 
within the hippocampus and dorsal cortex of transgenic mice that express human mutant 
APP and human APOE. The third aim will allow us to determine the effects of the AD-
like pathology, specifically Aβ plaques, on behavior, suggesting that reduction of Aβ 
could be of potential therapeutic benefit for AD. By understanding where the plaque 
deposition and cell loss is located, therapeutic benefits may target cognitive functioning 
associated with those regions of the brain. 
Achievement of these three aims will aid in a more formal understanding of the 
precursors to this disease, specifically APP and APOE. This will give incentive in 
developing more effective primary treatment and preventative interventions for AD. With 
effective primary treatment developed, there will be more motivation for individuals to 
get tested for their APP and APOE genes, allowing for an earlier detection of AD. This 
will likely decrease the prevalence of AD. Determining whether Alzheimer’s pathology is 
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correlated with behavioral deficits will improve technologies as well. Aside from 
developing effective treatment, technologies will be developed to make living with AD 
more manageable. By accepting the fact that behavioral deficits are inevitable, scientists 
and researchers may develop effective computer programs that make those behavioral 
deficits manageable in their day-to-day routine. 
If the first and second hypotheses are supported, then the detrimental effects of E4 
on the human brain may be accurately represented in this double transgenic KI mouse 
model. Since those who are homozygous for E4 do not invariably develop AD, the exact 
mechanism for how APOE alleles influence the risk of AD is still unclear (Kelly R. Bales 
et al., 2009; Corder et al., 1993; Kim et al., 2009; Mahley et al., 2006). According to Kim 
et al. (2009), strong evidence suggests that APOE influences the risk of AD via its effects 
on Aβ metabolism. ApoE gets lipidated by ABCA1 to form lipoprotein particles. ABCA1 
(ATP-binding cassette A1) transfers cellular cholesterol and phospholipids onto lipid-
poor apolipoproteins to form pre-HDL. This lipidated apoE binds to soluble Aβ, which 
influences the formation of parenchymal amyloid plaques and transport of Aβ within the 
CNS. Hence, increasing the lipidation state of apoE may influence the Aβ metabolism in 
the mouse brain or the ability of Aβ to form amyloid fibrils. It is believed that ABCA1 
deletion increases Aβ deposition by affecting the lipidation state of apoE (Wahrle et al., 
2005). However, the details of this mechanism are not clearly understood (Kim et al., 
2009).  
Strong evidence suggests that a major mechanism underlying the link between 
apoE and AD is related to the interaction between apoE and Aβ and apoE’s ability to 
influence Aβ’s clearance, aggregation, and conformation (D. Holtzman, 2004; Tokuda et 
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al., 2000). Different apoE isoforms alter AD pathogenesis via their interactions with Aβ 
peptide (Wahrle et al., 2005). The mechanism by which apoE interacts with Aβ is still not 
clearly understood, but murine apoE has been found to somehow influence Aβ to a β-
pleated sheet conformation (K. R. Bales et al., 1997; Kelly R. Bales et al., 1999). 
Holtzman (2004) investigated the effects of human apoE isoforms on Aβ deposition in 
vivo. Holtzman (2004) found that although PDAPP+/- mice in the presence or absence of 
murine apoE developed Aβ deposits by 9 months of age, PDAPP+/- mice with human E2, 
3, and 4 did not develop Aβ deposition until 15-24 months of age. At 15 months of age, 
the E3 and 4 mice developed Aβ deposition in the form of both diffuse and neuritic 
plaques, similar to that seen in the presence of murine apoE. By 18-22 months of age, 
some E2 mice had begun to develop diffuse plaques, but none had developed neuritic 
plaques. This data suggests the isoform-specific role in the apoE-Aβ interaction. 
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CHAPTER THREE 
INNOVATION 
The specific animal model used in the current study is distinct from previous 
studies investigating PDAPP mice expressing human E3 and E4 in that they did not 
assess behavior (Kelly R. Bales et al., 1999; Fagan et al., 2002; D M Holtzman et al., 
2000; David M Holtzman et al., 1999). Hartman et al. (2002) investigated PDAPP mice 
expressing human E3 and E4 as well, with the addition of TBI. In analyzing the 
neuropathology of AD in mouse brains, the current study addresses a novel way of 
producing the double-transgenic mice, representing a “cleaner” double-transgenic mouse 
model compared to what is normally seen in previous literature. In the current study, 
APOE KO mice had human variations of E3 and E4 replaced via KI technology. KO 
mice are mice whose DNA has been genetically engineered so it does not express a 
certain protein. These human variations of APOE were placed in the exact location within 
the mouse genome that the mouse APOE was removed from. Hypothetically, this resulted 
in an Aβ and APOE interaction more similar to what is seen in humans with AD. These 
mice were then crossbred with PDAPP transgenic mice. The advantage to using this 
specific double-transgenic mouse model is that it leads to a more accurate representation 
of the human Alzheimer’s brain. 
Additionally, this current study measures the cognitive and behavioral deficits 
resulting from this specific double-transgenic mouse model. Behavioral deficits have 
been investigated in the past, but of transgenic animal models that were different from 
what was used in the current study. Bales et al. (2009) had performed a study using a 
similar mouse model to ours, but did not study behavior. The current study will not only 
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assess the neuropathology of the disease brought about by the interaction of human 
APOE and human mutant APP, but also the resulting behavioral deficits.  
Previous research from our lab has characterized the neuropathological and 
behavioral profiles of various transgenic mouse models. In one study, Hartman et al. 
(2001) crossed APOE KO mice with transgenic mice expressing either human E3 or 
human E4 to examine the effects of human APOE in the absence of endogenous murine 
APOE. Compared to human APOE, murine APOE is most similar to E3 and 4, as shown 
in Holtzman (2004) where E3 and 4 mice developed diffuse and neuritic plaques similar 
to those seen in the presence of murine APOE.  
PDAPP+/- mice in the presence or absence of murine APOE all began to develop Aβ 
deposits by 9 months of age (D. Holtzman, 2004). Another study using an APP 
transgenic mouse model of AD showed that the absence of murine APOE does not result 
in a delay in the onset of Aβ deposition (David M Holtzman et al., 1999), but it does 
result in a decrease in the level of Aβ deposition (K. R. Bales et al., 1997). 
 Hartman et al. (2001) was the first to report the behavioral phenotyping of GFAP-
E3 and GFAP-E4 transgenic mice in which both isoforms of human APOE are expressed 
in glia. Glia is the predominant cell type in the CNS that synthesizes APOE in mammals. 
The GFAP (glial fibrillary acidic protein) gene provides information for the GFAP 
protein. This protein is an intermediate filament (cytoskeletal components, responsible 
for cell shape, division, and function) that is expressed by numerous cell types of the 
CNS including astrocytes (Jacque et al., 1978; Venkatesh et al., 2013). 
Hartman et al. (2001) carried out a longitudinal study where E3 and E4 mice were 
compared with APOE KO and WT mice (all male). Various behavioral measures were 
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conducted.  ApoE4 mice appeared to be the most “emotionally reactive” compared to E3, 
APOE KO, and WT mice. ApoE4 mice were also significantly impaired on working 
memory tasks. The presence of behavioral impairments and the lack of AD-like 
neuropathology displayed in the E4 mice suggests that the APOE genotype plays a role in 
the AD-related cognitive impairments in humans, which may be distinct from any effects 
on Aβ structure and deposition.  
Hartman et al. (2002) then looked at how APOE and TBI affect the development 
of AD. The model consisted of PDAPP mice expressing human E3, E4, or no APOE 
subjected to unilateral cortical impact injury. The TBI was induced at 9-10 months of age 
and monitored for 3 months. It was previously found that PDAPP mice expressing human 
ε3 and ε4 do not develop Aβ deposition until about 15 months of age (D M Holtzman et 
al., 2000). Hartman et al. (2002) found that, following TBI, a high percentage of brain-
injured PDAPP:ε4 mice had Aβ deposition by 12-13 months of age. The TBI appeared to 
accelerate Aβ deposition in the form of amyloid in the presence of human ε4 to a greater 
extent than ε3 (Richard E Hartman et al., 2002). Also, they found that the PDAPP mice 
that did not express human APOE had significantly greater Aβ load than those that 
expressed ε3 and ε4. However, the Aβ deposits were non-fibrillar, consisting of only 
thioflavin-S-negative Aβ (Richard E Hartman et al., 2002). 
Thioflavin-S-positive Aβ was only present in the dentate gyrus in the PDAPP:ε4 
mice, specifically 44% of the 56% of the Aβ-immunoreactive deposits (Richard E 
Hartman et al., 2002). Thioflavin-S-positive Aβ suggests the presence of fibrillar amyloid 
deposition. The dentate gyrus is located in the inner portion of the hippocampus, as 
depicted by the letters “DG” in Figure 4. No PDAPP:ε3 mice had fibrillar amyloid 
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deposition. There also existed no significant difference in the amount of brain tissue or 
cell loss across the groups. Given that the presence or absence of APOE isoforms was the 
only difference between the groups of PDAPP mice, they found that the isoform-specific 
APOE-Aβ interactions contribute to the premature development of AD pathology 
(Richard E Hartman et al., 2002).  
In heterozygous PDAPP mice, Aβ deposition in the molecular layer of the dentate 
gyrus was compared in mice expressing no APOE, murine APOE, or various isoforms of 
human APOE (Fagan et al., 2002). Aβ deposition was the most robust in the molecular 
layer of the dentate gyrus in animals expressing mouse APOE and increased with age 
(Figure 5). PDAPP mice expressing E4 also displayed increases in Aβ deposition, but to 
a much less magnitude than that observed in the murine APOE mice. The amount of Aβ 
deposition in the dentate gyrus was low in the absence of APOE up to 18 months, but 
increased by 21 months (Fagan et al., 2002).  
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Figure 5. The Aβ deposition in the molecular layer of the dentate gyrus, in heterozygous 
PDAPP mice, was compared in mice expressing no apoE, murine apoE, or various 
isoforms of human apoE. PDAPP mice expressing apoE4 also displayed increases in Aβ 
deposition, but to a much less magnitude than that observed in the murine apoE mice 
(Fagan et al., 2002).  
 
 
Hartman et al. (2002) differs from the current study in that a TBI is induced and 
that the transgenic mice were not “targeted” replacement/KI mice. Also, they found no 
significant difference in the amount of cell loss across groups (PDAPP:ε3, PDAPP:ε4, 
PDAPP:ε-/-). This lack of difference may be due to the fact that the TBI may have had a 
larger affect on the PDAPP:ε3 and PDAPP:ε-/- mice, diminishing the difference of cell 
loss across groups. TBI was not induced in the current study, allowing us to investigate 
the cellular loss solely based on the double transgenic mice, with no other interfering 
variables. 
Hartman et al. (2005) then characterized Aβ plaque load and learning deficits in 
the PDAPP transgenic mouse model. They found that the PDAPP mice had a substantial 
age-dependent decline in learning ability. To determine whether the age-related spatial 
learning deficits were due to the Aβ accumulation, Hartman et al. (2005) treated WT and 
PDAPP mice with a passive anti-Aβ antibody (10D5), which specifically targets Aβ by 
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binding to amino acids 3-6 in the n-terminus (towards the beginning of the Aβ peptide) 
(Hyman, Tanzi, Marzloff, Barbour, & Schenk, 1992). Over several weeks of treatment 
with 10D5, aged PDAPP mice improved in hippocampal long-term potentiation and 
behavioral performance with substantial Aβ burden. This suggests that Aβ had in fact 
contributed to the age-dependent learning deficits displayed in PDAP mice. Should our 
first hypothesis (PDAPP:E4 mice will show more Alzheimer’s-like pathology in the 
hippocampus and dorsal cortex than the PDAPP:E3 mice) be correct, the findings from 
Hartman et al. (2005) would aid in supporting the third hypothesis (Alzheimer’s-like 
pathology will be positively correlated with the behavioral deficits displayed in the mice). 
The advantage to using this mouse model over the aforementioned models is 
establishing a baseline behavioral and neuropathological data for a new double-transgenic 
mouse model for AD. This study has important implications for understanding the effects 
of new therapeutic medications on the behavior of those suffering from AD. Various 
therapeutic techniques have already shown productive in AD mouse models. When 
administered early in the AD course of a Tg2576 transgenic mouse model, ibuprofen, a 
non-steroidal anti-inflammatory drug (NSAID), has led to a significant delay in amyloid 
deposition (G. P. Lim et al., 2000). It was also found that antioxidants including 
melatonin (Matsubara et al., 2003), curcumin (G. P. Lim et al., 2001), vitamin C/E 
(Harkany et al., 1999), blueberry extract (Joseph et al., 2003), and pomegranate juice 
(Richard E Hartman et al., 2006) reduced Aβ levels in Tg2576 mice.  
Lastly, APOE mimetics have shown to be effective in AD mouse models. ApoE 
mimetics are small peptides, derived from the receptor-binding region of APOE, that 
mimic the neuroprotective, anti-oxidant, and anti-inflammatory properties of intact APOE 
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(Aono et al., 2003; Croy, Brandon, & Komives, 2004; D T Laskowitz et al., 2001; Lynch 
et al., 2003, 2005; McAdoo et al., 2005). ApoE133-149 (COG133) is a 17-amino-acid 
peptide that has demonstrated in vivo anti-inflammatory and neuroprotective activity in 
animal models of AD (Vitek et al., 2012), TBI (Lynch et al., 2005), and hypoxic-
ischemic injury (HIE; McAdoo et al., 2005). Starting at 9 months, Vitek et al. (2012) 
administered COG133 subcutaneously 3 times per week for 3 months to CVND-AD 
(SwDI-APP/NOS2-/-) transgenic mice. Following treatment, these animals maintained 
significantly more of their neurons, grew fewer plaques and neurofibrillary tangles, and 
navigated better in the radial arm water maze than did untreated animals (Vitek et al., 
2012). COG1410, a shorter analogue to COG133, is a 12-amino-acid peptide that is also 
active in animal models, but with increased potency and extended latency between injury 
and time to treatment (D. T. Laskowitz, Fillit, Yeung, Toku, & Vitek, 2006; Daniel T 
Laskowitz et al., 2007). ApoE mimetics represent a novel therapeutic strategy to 
neurological disorders including AD. 
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CHAPTER FOUR  
DESIGN 
Animals 
Transgenic mice expressing human amyloid precursor protein (APP) with a 
mutation (V717F) that causes early onset familial Alzheimer’s disease (AD) were 
crossbred with transgenic mice expressing human apolipoprotein E (E3 or E4) to create 
double-transgenic mice (PDAPP:E3 and PDAPP:E4). Initially, 30 PDAPP:E3 and 16 
PDAPP:E4 double-transgenic mice, 21-24 months of age, were obtained from Eli Lilly 
Corporation. They were housed on a 12:12 light:dark schedule and fed standard rodent 
chow and water ad libitum. These mice underwent a battery of behavioral and cognitive 
tests that was approved by Loma Linda University Institutional Animal Care and Use 
Committee (IACUC), including the rotarod (assessing balance and sensorimotor 
coordination), open field (assessing general activity levels and movement patterns), 
elevated zero maze (assessing general anxiety levels), and water maze (assessing learning 
and memory). The brains of a subset of these mice were assessed in the current study (n = 
5 PDAPP:E3; n = 4 PDAPP:E4; all males). 
 
Tissue Processing and Histology 
Animals were sacrificed via intra-cardiac perfusion. The brains were removed and 
immersed in paraformaldehyde, fixed in a 30% sucrose solution at 4ºC for about 18 
months, and then frozen on dry ice and stored at -20ºC.  Coronal sections, 50 microns 
thick, were sectioned from the brains’ anterior (prefrontal cortex [PFC]) to the posterior 
(cerebellum) using a cryostat. Coronal sections are taken along the frontal plane of the 
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brain, dividing the brain into anterior and posterior portions. The free-floating sections 
were preserved by placing them in a solution of 400 mL phosphate buffer solution (PBS), 
400 mL sodium azide (NaN3), and 3,000 mL double distilled water (ddH2O). Each well 
contained four to five anterior, middle, and posterior slices from each brain.  
A subset of free-floating sections was stained for diffuse early stage Aβ deposits 
(pre-clinical) using HJ3.4, an antibody that binds to the 1st 13 amino acids of Aβ’s N-
terminus (i.e., Aβ1-13) and has a fluorescent tag (Tran, Sanchez, Esparza, & Brody, 
2011). These plaques lack a morphologically identifiable substructure, resembling a ball 
of cotton (Dickson & Vickers, 2001). HJ3.4 staining began with thoroughly washing the 
sections in PBS. To enhance antigen (e.g., Aβ) binding, the sections were blocked at 
room temperature in a humid chamber in 1% bovine serum albumin (BSA) in PBS 2 x 10 
minutes for 90 minutes. BSA enhances antigen detection by binding to and blocking 
other epitopes (binding sites). The sections were then incubated overnight at 4ºC with 
HJ3.4 antibody (1:1000) in 0.25% BSA/0.25% TritonX-100 in PBS. TritonX-100 is a 
detergent used to enhance antibody penetration during immunohistochemistry by acting 
as a surfactant (reduces surface tension of a liquid in which it is dissolved). Following 
another thorough wash in PBS 2 x 10 minutes and ddH20 2 x 1 minute (to remove PBS 
salts), sections were mounted on Superfrost slides and allowed to dry. About 20 
microliters of Vectashield, a mounting medium that prevents photobleaching, was placed 
on each section and disbursed equally with a cover slip placed over it. Once dry, clear 
nail polish was used around the edges of the coverslip to hold it in place. The Vectashield 
contained 4’,6-diamidino-2-phenylindole (DAPI), a fluorescent stain that stains DNA in 
cell nuclei. DAPI was used to analyze the cellular count of the tissue. The slides were 
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then stored in 4ºC. Figure 6 illustrates the HJ3.4 staining of diffuse Aβ in the 
hippocampus of a PDAPP:E4 mouse from the current study. 
 
 
Figure 6. HJ3.4 staining of diffuse deposits in the hippocampus of a PDAPP:E4 double 
transgenic mouse from the current study. 
 
 
Another subset of brain sections was stained for fibrillar (late stage “amyloid”) 
Aβ plaques using thioflavin-S. These mature amyloid plaques have a dense core (A. E. 
Roher et al., 2004) that can be identified by their compacted central mass of β-amyloid 
(Dickson & Vickers, 2001) surrounded by neuritic processes (i.e., injured 
axons/dendrites). Figure 7 illustrates fibrillar Aβ deposits stained with thioflavin-S in 
transgenic mice. Figure 8 illustrates fibrillar Aβ as well, in pomegranate-treated mice. 
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Figure 7. A. Thioflavin-S staining compact deposits in CA1 of the hippocampus of 
APPV717F+/+ APOE-/- transgenic mice. Scale bar = 100µm (Irizarry et al., 2000). B. 
Thioflavin-S positive amyloid plaque. Scale bar = 20 µm (Oakley et al., 2006). C. 
Coronal sections of the dorsal hippocampus stained with Thio-S. (Groen et al., 2003). 
 
 
Figure 8. Brain Aβ load. Brains from mice treated with control and pomegranate juice. 
Mice treated with pomegranate juice had significantly total Aβ (top row) and fibrillar 
(thioflavin-S-positive) Aβ (bottom row) in the hippocampus and dorsal cortex than the 
control mice (Richard E Hartman et al., 2006). 
 
A 
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Assessing these two stages of plaques not only allows us to differentiate between early 
and end stages of Aβ plaques in AD, but to determine whether our hypotheses hold true 
for both stages of Aβ plaques.  
Thioflavin-S staining began by thoroughly washing sections in PBS and then in 
ddH2O to remove PBS and acclimate to the ddH2O. Ethanol (EtOH) was used to 
dehydrate the sections. The sections were then stained with a solution of 1% thioflavin-S. 
To clean any excess stain, the sections were then washed with ddH2O. After staining for 
thioflavin-S, the sections were mounted onto slides and allowed to dry. About 20 
microliters of Vectashield was placed on each section and disbursed equally with a cover 
slip placed over it. Once dry, clear nail polish was used around the edges of the coverslip 
to hold it in place. The slides were then stored in 4ºC. 
 
Aβ Quantification and Cellular Density 
For quantification of Aβ, histology slides were initially evaluated using a Zeiss 
LSM 710 confocal microscope, provided by the Loma Linda University School of 
Medicine Advanced Imaging and Microscopy Facility. Due to unforeseen technical 
difficulties, imaging of Aβ deposits was completed using an Olympus FluoView FV-
1000 confocal microscope, provided by Dr. Hongwei Dong of Zilkha Neurogenetic 
Institute at the Keck School of Medicine of University of Southern California.  
Images of the entire extent of the hippocampus and dorsal cortex (defined as 
cortical tissue directly over the dorsal hippocampus) were assessed at 40x magnification. 
ImageJ, an image processing and analysis software, and Adobe Photoshop were used to 
quantify fibrillar and total Aβ load, defined as the percentage of each tissue section 
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covered by deposits. The Aβ load was calculated by dividing the total area of tissue 
covered by deposits (quantified in ImageJ) by the total area of the region of interest 
(hippocampus or dorsal cortex; quantified in Adobe Photoshop).  
For quantification of cellular density, histology slides were evaluated using a 
Keyence BZ-X700 Fluorescence Microscope, provided by Dr. Andre Obenaus’ Non-
Invasive Imaging Laboratory in the Radiation Biology Program at Loma Linda 
University. Images of the hippocampus and dorsal cortex were assessed at 40x 
magnification. Images were taken of three areas in the hippocampal CA1 region (CA1-A, 
CA1-B, and CA1-C; Figure 9a) at three depths (approximately every 7.5 µm below the 
surface of the 50 µm thick tissue sections; Figure 10). Cells were quantified for each 
layer using the “cell counter” plugin in ImageJ and summed together. This sum was then 
divided by the volume of the CA1 to determine the cellular density in cells/mm3. The 
same procedure was done for the dorsal cortex region (DCx-A, DCx-B, and DCx-C; 
Figure 11a).  
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Figure 9. A. CA1-A, CA1-B, and CA1-C along the CA1 region of animal “5-4,” a 
PDAPP:E4 mouse. Image taken at 2x magnification. B. CA1-B of the hippocampus of 
animal “5-4.” Image taken at 40x magnification. Blue dots indicate stained cell nuclei. 
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Figure 10. This is an image of a cross-section of a brain slice to help visualize how the 
brain sections were analyzed in the current study. In the current study, the brain section 
was 50 um thick. Images were analyzed at three depths (approximately every 7.5 µm 
below the surface of the section).  
 
 
 
 
Figure 11. A. DCx-A, DCx-B, and DCx-C in the dorsal cortex (DCx) of animal “5-4,” a 
PDAPP:E4 mouse. Image taken at 2x magnification. B. DCx-B of animal “5-4.” Image 
taken at 40x magnification. Blue dots indicate stained cell nuclei. 
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Statistical Analysis 
IBM SPSS Statistics version 20 will be used to analyze the collected data. All 
data will be presented as mean +/- standard error of the mean (SEM), and graphs will be 
generated using GraphPad version 6.0d. An α-level of .05 will be used for all significance 
tests. For the Aβ load analysis, independent-samples t-tests were conducted to compare 
the total Aβ load in HJ3.4-stained PDAPP:E4 and PDAPP:E3 brain sections in the 
hippocampus and dorsal cortex. Independent-samples t-tests were also conducted to 
compare fibrillar Aβ (amyloid) load in thioflavin-S-stained brain sections. Although two 
t-tests were performed, a bonferroni correction was not used since previous research has 
shown that two t-tests are not enough to cause a real problem with type I error. 
An independent samples t-tests was also used to test between-group differences of 
cellular density of PDAPP:E4 and PDAPP:E3 mice in the CA1 and dorsal cortex. An 
independent t-test was first conducted to analyze the total cellular density from two areas 
of the CA1 or dorsal cortex as a function of APOE type. A multivariate analysis of 
variance (MANOVA) was then conducted to determine whether cell densities between 
PDAPP:E4 and PDAPP:E3 mice in the CA1 or dorsal cortex still differed when the two 
areas within the region were analyzed separately. For the CA1 analyses, an independent 
samples t-test was then conducted to determine whether there was a significant difference 
between the cellular density in PDAPP:E4 and PDAPP:E3 mice in only CA1-C.  
Lastly, for determining whether there is a correlation between neuropathology and 
behavioral deficits, bi-correlation analysis will be used to measure the strength and 
direction of the relationship between neuropathology and behavioral deficits. 
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A total of 9 animals (E3 n = 5; E4 n = 4) will be assessed. Sections stained with 
HJ3.4 and thioflavin-S will be included for each animal. Independent-samples t-tests 
were conducted to compare the total Aβ load in HJ3.4-stained PDAPP:E4 and PDAPP:E3 
brain sections in the hippocampus and dorsal cortex. The probability that the independent 
samples t-test will find statistically significant differences in Aβ load and cellular count 
in the two groups, given that a difference exists, is 71% (power = 0.71; effect size = 0.8; α 
= 0.05; n = 9). Given that a specific direction is hypothesized (i.e., that PDAPP:E4 mice 
will show significantly more Aβ staining than PDAPP:E3 mice) a one-tailed test will be 
used. Regarding the third hypothesis, power analysis showed that studying nine animals 
would give a statistical power sufficient to have a 97% chance of detecting a correlation 
between neuropathology and behavioral deficits. Outliers, defined as any data point that 
fell within a distance of three times the interquartile range from the first and third 
quartiles, were removed. 
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CHAPTER FIVE 
RESULTS 
Given that the following analyses were based on planned comparisons, 
Bonferroni corrections were not used for Hypothesis One, Two, or Three.  
 
Hypothesis One 
One PDAPP:E3 mouse was removed from the overall Aβ analysis for being 1.6 
standard deviations above the hippocampal mean and 1.8 standard deviations above the 
dorsal cortex mean. Two PDAPP:E3 mice were removed from the dorsal cortex fibrillar 
Aβ analysis, one for being 1.6 standard deviations above the mean and another one for 
being 1.1 standard deviations below the mean. 
The hypothesis that PDAPP:E4 mice would have more Aβ plaques (total and 
fibrillar) in their brains than PDAPP:E3 mice was partially confirmed. A trend was 
observed in the hippocampus suggesting that PDAPP:E4 mice had more total Aβ load 
(defined as the % area stained by HJ3.4) than PDAPP:E3 mice (PDAPP:E4 M=3.023%, 
SD=2.232; PDAPP:E3 M=.875%, SD=.738; t(6)=-1.827, p>.1; Figure 12a). A significant 
difference was found in the dorsal cortex suggesting PDAPP:E4 mice had more total Aβ 
load than PDAPP:E3 mice (PDAPP:E4 M=2.19%, SD=1.055; PDAPP:E3 M=.533%, 
SD=.230; t(6)=-3.069, p<.02; Figure 12b). However, levels of fibrillar Aβ (amyloid) did 
not differ between the groups. 
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Figure 12. A. There was no significant difference in total Aβ hippocampal load between 
HJ3.4-stained PDAPP brain sections expressing human E4 and those expressing human 
E3. B. HJ3.4-stained PDAPP:E4 brain sections had a significantly greater total Aβ load 
in the dorsal cortex than PDAPP:E3 sections. Note: *p<.025. Data points in red are 
outliers excluded from analysis. 
 
 
Interestingly, amyloid load in both the hippocampus and dorsal cortex was lower 
in PDAPP:E4 mice than in PDAPP:E3 mice, although the difference was not significant 
(Hippocampus: PDAPP:E4 M=.5%, SD=0.215; PDAPP:E3 M=1.42%, SD=.991; t(7)=1.8, 
p>.10; Dorsal cortex: PDAPP:E4 mice M=.833%, SD=0.353; PDAPP:E3 M=.897%, 
SD=.055; t(5)=.305, p>.6; Figures 13a and 13b, respectively). 
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Figure 13. A. No significant difference in fibrillar Aβ load in the hippocampus or B. 
dorsal cortex only out of thioflavin-S-stained animals between PDAPP:E4 and 
PDAPP:E3 brain sections. Data points in red are outliers excluded from analysis. 
 
Given that only one statistically significant difference was found in assessing 
whether expression of human APOE will alter plaque load in the hippocampus and dorsal 
cortex of PDAPP mice, the fibrillar Aβ:total Aβ ratio was analyzed. The previously 
excluded outliers were included in this analysis to assess the overall fibrillar β:total Aβ 
ratio for each group of mice. The ratios were analyzed by calculating the sum of the 
fibrillar Aβ load and total Aβ load in the hippocampus and dorsal cortex to determine 
whether there was a statistically significant difference between PDAPP:E4 and 
PDAPP:E3 mice (Table 3).  
 
Table 3. Overall fibrillar Aβ:total Aβ ratio. 
Genotype Hippocampus Dorsal Cortex Both Regions 
PDAPP:E4 0.17 0.38 0.26 
PDAPP:E3 0.93 0.74 0.84 
 
Findings indicated both groups of mice had a higher total Aβ load than fibrillar Aβ load, 
as expected, in both the hippocampus and dorsal cortex. Also, in both regions, a trend 
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indicates that PDAPP:E4 mice have a lower fibrillar Aβ:total Aβ ratio (Ratio=0.26) than 
PDAPP:E3 mice (Ratio = 0.84). 
To summarize the results of Hypothesis One, PDAPP:E4 mice had more total Aβ 
than PDAPP:E3 mice in both the hippocampus and dorsal cortex, although only the 
cortical difference was statistically significant. In contrast, PDAPP:E4 mice had less 
fibrillar Aβ than PDAPP:E3 mice in both the hippocampus and dorsal cortex, although 
neither difference was statistically significant. Lastly, a trend indicates that PDAPP:E4 
mice have a lower fibrillar Aβ:total Aβ than PDAPP:E3 mice. 
 
Hypothesis Two 
The hypothesis that PDAPP mice that also express human E4 will have a lower 
cellular density in their CA1 and dorsal cortices than PDAPP mice that also express 
human E3 was partially confirmed. Specifically, PDAPP:E4 mice had a lower cellular 
density than PDAPP:E3 mice in the CA1 and dorsal cortex, but the difference was not 
statistically significant.  
Since the cellular densities for CA1-A (the most lateral area in the CA1; Figure 
9a) were very similar between PDAPP:E4 and PDAPP:E3 mice (not statistically 
different), only CA1-B and -C were included in the analyses. The cellular density from 
CA1-B and -C were summed together and then divided by the CA1 volume to get the 
total CA1 cellular density. As hypothesized, PDAPP mice that also expressed E4 had a 
lower cellular density in the CA1 than PDAPP mice that also expressed E3 (PDAPP:E4 
M=201,132.61 cells/mm3, SD=49,021.35; PDAPP:E3 M=259,563.30 cells/mm3, 
SD=51,498.67; t(6)=1.56, p<.17), although the difference was not statistically significant. 
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When determining whether the cellular density between PDAPP:E4 and 
PDAPP:E3 mice in the CA1 still differed when CA1-B and -C were analyzed separately, 
PDAPP:E4 mice still had a lower cellular density in CA1-B and -C separately than 
PDAPP:E3 mice (CA1-B: PDAPP:E4 M=108,034.20 cells/mm3, SD=16,741.02; 
PDAPP:E3 M=126,861.45 cells/mm3, SD=12,967.54; CA1-C: PDAPP:E4 M=93,098.41 
cells/mm3, SD=14,774.98; PDAPP:E3 M=132,701.85 cells/mm3, SD=11,444.65; 
F(2,5)=2.23, p<.21; Wilk’s ∆=.53; Figure 14). However, the difference was not 
statistically significant. 
 
 
 
Figure 14. PDAPP:E4 mice had a lower cellular density in CA1-B and -C of the 
hippocampus separately than PDAPP:E3 mice, but the difference was not statistically 
significant. 
 
 
When assessing the difference between the cellular density in PDAPP:E4 and 
PDAPP:E3 mice in CA1-C only, findings suggested that PDAPP:E4 mice still had a 
lower cellular density in CA1-C (medial), but the difference was not statistically 
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significant (PDAPP:E4 M=93,098.41 cells/mm3, SD=21,951.43; PDAPP:E3 
M=132,701.85 cells/mm3, SD=27,228.98; t(6)=2.12, p<.08; Figure 15). 
 
 
 
Figure 15. PDAPP:E4 mice had a lower cellular density than PDAPP:E3 mice in CA1-C 
of the hippocampus, but the difference was not statistically significant. 
 
 
A non-parametric test (Kruskal Wallis) was conducted to determine whether a 
statistically significant difference could be found with CA1-B and -C combined when 
accounting for the small sample size. The Kruskal Wallis test corroborated these results 
(CA1-B: χ2(1)=1.09, p<.30; CA1-C: χ2(1)=2.69, p<.11).  
The cellular density in the dorsal cortex was assessed next. Since cellular 
densities for DCx-C (the most medial area in the dorsal cortex; Figure 11a) were very 
similar between PDAPP:E4 and PDAPP:E3 mice (not statistically different), only DCx-A 
and -B were included in the analyses. The cellular density from DCx-A and -B were 
summed and then divided by the total cortical volume to get a total cortical cellular 
density. PDAPP mice that also expressed E4 had a lower cellular density in the dorsal 
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cortex than PDAPP mice that also expressed E3 (PDAPP:E4 M=461,209.30 cells/mm3, 
SD=146,835.99; PDAPP:E3 M=533089.43 cells/mm3, SD=218,760.67; t(6)=.50, p<.64), 
although the difference was not statistically significant. 
Next, we determined whether cellular density between PDAPP:E4 and PDAPP:E3 
mice in the dorsal cortex differed when DCx-A and -B were analyzed separately. 
Transformational analyses were used to include the previously excluded outliers by 
taking the square root of each value. Findings suggested a trend such that PDAPP:E4 
mice had a lower cellular density than PDAPP:E3 mice in DCx-A and DCx-B (DCx-A: 
PDAPP:E4 M=459.32 cells/mm3, SD=47.18; PDAPP:E3 M=503.51 cells/mm3, 
SD=36.54; DCx-B: PDAPP:E4 M=491.61 cells/mm3, SD=72.28; PDAPP:E3 M=507.82 
cells/mm3, SD=55.99; F(2,5)=.33, p>.73; Wilk's ∆=.883; Figure 16), although the 
difference was not statistically significant.  
 
 
 
Figure 16. There were no statistically significant differences in cellular density between 
PDAPP:E4 and PDAPP:E3 mice within DCx-A and –B following a transformational 
analysis. However, a trend suggested that PDAPP:E4 mice had a lower cellular density 
than PDAPP:E3 mice. 
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A non-parametric test (Kruskal Wallis) was conducted to determine whether a 
statistically significant difference could be found when accounting for the small sample 
size. These results also suggested no statistically significant difference in the cellular 
density in DCx-A or -B between PDAPP:E4 and PDAPP:E3 mice (DCx-A: χ2(1)=.20, 
p>.65; DCx-B: χ2(1)=.02, p>.88). 
To summarize the results of Hypothesis Two, PDAPP:E4 mice had a lower 
cellular density than PDAPP:E3 mice in the CA1 and dorsal cortex, although not 
statistically significant (Table 4).  
 
Table	4.	Means	and	standard	deviations	from	Hypothesis	Two	analyses.	
		 		
PDAPP	x	ApoE4	
Cell	Count	
PDAPP	x	ApoE3	
Cell	Count	
	
Tissue	Region	
Area	of	
Region	 M	 SD	 M	 SD	
p-
value	
Hippocampus	
CA1-B	and	-
C	combined	 430	 101.43	 558.6	 58.76	 0.06	
	
CA1-B	only	 237.33	 61.81	 279.6	 21.45	 0.20	
	
CA1-C	only	 192.67	 40.5	 279	 54.52	 0.06	
Dorsal	Cortex	
DCx-A	and	-
B	combined	 1101.33	 45.08	 961.8	 426.36	 0.51	
	
DCx-A	only	 547	 44.17	 573.2	 125.29	 0.69	
	 DCx-B	only	 587.67	 46.09	 538.2	 195.45	 0.69	
Note.	¥	=	Transformational	analyses	were	conducted	such	that	the	square	root	was	
taken	of	each	value	
	
 
Hypothesis Three 
The hypothesis that mice with more Alzheimer’s-like neuropathology 
(specifically Aβ plaques and/or lower cellular density) will have worse behavioral 
deficits was confirmed.  
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Correlation analyses were conducted to determine whether the degree of 
neuropathology was correlated with behavioral performance. In PDAPP:E3 mice, a 
higher amyloid load in the dorsal cortex was associated with less activity in the open field 
tasks (average distance traveled: r=.95, p<.02; Figure 17; average duration traveled: 
r=.92, p<.03; Figure 18).  
 
 
 
Figure 17. In PDAPP:E3 mice, a higher amyloid load in the dorsal cortex was associated 
with less distance traveled in the open field task (r=.95, p<.02). 
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Figure 18. In PDAPP:E3 mice, a higher amyloid load in the dorsal cortex was associated 
with time spent moving in the open field task (r=.92, p<.03). 
 
 
Interestingly, across both groups of mice, a higher amyloid load in the dorsal 
cortex trended toward an association with better performance on the rotarod task, 
although the correlation was not statistically significant (r=.65; p>.05; Figure 19a). When 
breaking up the regions by stain and APOE allele, other statistically significant 
correlations were found. Specifically, a higher total Aβ load in the hippocampus among 
PDAPP:E3 mice was associated with better performance on the rotarod when rotating at 
a steady rate (r=.88, p<.05; Figure 19b). Among PDAPP:E4 mice, a higher total Aβ load 
in the dorsal cortex was associated with worse performance on the rotarod when rotating 
at an accelerated rate (r=-.97, p<.04; Figure 19c) and when rotating at a faster accelerated 
rate (r=-.97, p<.03; Figure 19d), following transformational analysis consisting of taking 
the square root of each value. 
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Figure 19. A. Across both groups of mice, a higher amyloid load in the dorsal cortex 
trended toward an association with better performance on the rotarod task, although the 
correlation was not statistically significant (r=.65; p>.05). B. Among PDAPP:E3 mice, a 
higher total Aβ load in the hippocampus was statistically significantly correlated with 
better performance on the rotarod when rotating at a steady rate (r=.88, p<.05). C. 
Among PDAPP:E4 mice, a higher total Aβ load in the dorsal cortex was statistically 
significantly correlated with worse performance on the rotarod when rotating at an 
accelerated rate (r=-.97, p<.04) and D. when rotating at a faster accelerated rate (r=-.97, 
p<.03) following transformational analyses consisted of taking the square root of each 
value. 
 
 
There were no significant correlations between total Aβ load or amyloid load in 
the dorsal cortex or hippocampus with water maze or zero maze performance. 
Correlation analyses were then conducted to determine whether cellular densities 
in the CA1 or dorsal cortex were correlated with behavioral deficits. Findings suggested a 
statistically significant correlation, such that a lower cellular density in the CA1 was 
 71 
associated with worse performance during the probe trials (a lower percent time in the 
target quadrant; r=-.81, p<.02; Figure 20) of the water maze. Additionally, a trend 
suggested that lower cellular density in the CA1 was associated with worse performance 
(traveling a greater distance) in the cued task (r=-.69, p<.059; Figure 21) and in the 
spatial task (r=-.63, p<.094; Figure 22). There were no significant correlations between 
the cellular density in the CA1 and any other behavioral performance. There were no 
significant correlations between total cellular density in the dorsal cortex and any 
behavioral performance. 
 
 
Figure 20. Across both groups of mice, lower cellular density in the CA1 was 
associated with worse performance (lower percent time in the target quadrant) during the 
probe trials of the water maze (r=-.81, p<.02). 
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Figure 21. Across both groups of mice, lower cellular density in the CA1 was associated 
with worse performance (traveling a greater distance) in the cued task of the water maze 
(r=-.69, p<.059). 
 
 
 
 
 
Figure 22. Across both groups of mice, lower cellular density in the CA1 was associated 
with worse performance (traveling a greater distance) in the spatial task of the water 
maze (r=-.63, p<.094). 
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 Correlation analyses revealed no relationships between Aβ or amyloid load and 
cellular density in the CA1 and dorsal cortex. There were also no statistically significant 
correlations between fibrillar Aβ and total Aβ.  
Repeated measures analyses suggested that PDAPP:E4 mice had more severe 
spatial learning deficits than PDAPP:E3 mice (Figure 23), as corroborated by Figure 22. 
PDAPP:E4 mice also spent more time in the open quadrants of the zero maze than 
PDAPP:E3 mice (F(1,7)=5.99, p<.045; Figure 24).  
 
 
Figure 23. Repeated measures analyses suggested that PDAPP:E4 mice had worse spatial 
learning performance than PDAPP:E3 mice. 
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Figure 24. PDAPP:E4 mice spent more time in the open quadrants (less time in the dark) 
in the zero maze compared to PDAPP:E3 mice (p<.05). 
 
To summarize the results of Hypothesis 3, PDAPP mice expressing E4 had worse 
behavioral deficits than PDAPP mice expressing E3, which correlated with their 
Alzheimer’s-like neuropathology. In both sets of mice, those with more Alzheimer’s-like 
neuropathology (specifically Aβ plaques and/or lower cellular density) had worse 
behavioral deficits. 
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CHAPTER SIX 
DISCUSSION 
The current study was designed to test the hypothesis that PDAPP:E4 mice would 
have greater neuropathology (including greater Aβ plaque load and lower cellular density 
in the brain) than PDAPP:E3 mice. Based on previous literature, the presence of E4 leads 
to greater Aβ production than does E3 in transgenic mice and humans (Bales et al., 1999, 
2009; Mahley, Weisgraber, & Huang, 2006; Schmechel et al., 1993; Tiraboschi et al., 
2004; Ye et al., 2005). Also, Hartman et al. (2002) concluded that in the presence of 
traumatic brain injury, fibrillar Aβ was only present in the PDAPP:E4 mice and not the 
PDAPP:E3 mice.     
Previous studies have shown that Aβ aggregation induces cell death (Estus et al., 
1997; LaFerla, Hall, Ngo, & Jay, 1996; Loo et al., 1993). Hippocampal cell loss has also 
been reported in AD patients (Mann, 1996; West, Coleman, Flood, & Troncoso, 1994). 
Hippocampal cell loss has also been reported in animal models such as in in vitro rat 
(Estus et al., 1997) and mouse (Ji et al., 2002; Loo et al., 1993) AD models as well as in 
in vivo mouse (Casas et al., 2004; LaFerla et al., 1996; Schmitz et al., 2004) AD models.  
Our findings indicate that PDAPP:E4 brains had more total Aβ (diffuse and 
fibrillar Aβ) in the hippocampus and dorsal cortex than PDAPP:E3 brains, and that the 
difference was greatest in the dorsal cortex. These findings were corroborated by the 
fibrillar Aβ:total Aβ ratio analysis (Table 3). There was no statistically significant 
difference in fibrillar Aβ between PDAPP:E4 and PDAPP:E3 brains, but a trend suggests 
that PDAPP:E4 brains had less fibrillar Aβ in the hippocampus and dorsal cortex than 
PDAPP:E3 brains.  
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Findings also indicated no difference in cellular density between PDAPP:E4 and 
PDAPP:E3 brains in the CA1 or dorsal cortex. However, a trend was observed such that 
PDAPP:E4 brains had a lower cellular density than PDAPP:E3 brains in the CA1 and 
dorsal cortex. 
Years of evidence have suggested that Aβ accumulation in the brain is the main 
causal factor of AD (Kim et al., 2011; Kuszczyk et al., 2013). One potential explanation 
for the trend that PDAPP:E4 brains had less fibrillar Aβ in the hippocampus and dorsal 
cortex than PDAPP:E3 brains is that Aβ accumulation may present as part of an adaptive 
response to chronic brain stress such as oxidation by free radicals, metabolic 
dysregulation, and/or genetic factors. Some studies have even suggested that Aβ is 
important for healthy brain functions, and that the removal of Aβ can interfere with brain 
homeostasis (Castello & Soriano, 2013; Castello, Jeppson, & Soriano, 2014).  
Another potential explanation for the trend found in the current study is that 
amyloid accumulation may serve as a neuroprotectant (Castellani et al., 2009). Castellani 
et al. (2009) suggests that Aβ is not responsible for the clinical manifestation of AD since 
it may protect cells from toxic intermediates. They concluded that since amyloid 
accumulation is a byproduct of upstream pathogenic events, it protects cells from the 
toxic protofibrils (transient structures during the formation of mature amyloid fibrils) or 
oligomers. In other words, the fibrils may be a better alternative to more neurotoxic 
smaller aggregates. 
The fibrillar Aβ:total Aβ ratio analysis trended toward a lower ratio in PDAPP:E4 
mice than in PDAPP:E3 mice, meaning that PDAPP:E4 mice had a lower proportion of 
fibrillar Aβ in the total Aβ load than PDAPP:E3 mice. These findings contradict the idea 
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that the presence of the apoe4 allele should lead to a greater Aβ accumulation than the 
presence of the E3 allele (Ji et al., 2002). However, these data may support the idea that 
amyloid accumulation serves a protective role in the brain. Since the E4 allele is 
associated with more neurotoxicity than the E3 allele, they serve less as a neuroprotectant. 
However, it is possible that the HJ3.4 stain was not potent enough or that the thioflavin-S 
staining protocol yielded too much background staining. 
The current study also tested the hypothesis that mice with more Alzheimer’s-like 
neuropathology (specifically Aβ plaques and/or lower cellular density) will have worse 
behavioral deficits.  Hartman et al. (2005) found that Aβ plaques displayed in PDAPP 
mice contributed to behavioral deficits. Similarly, G. Chen et al. (2000) found a negative 
correlation between spatial learning capacity and plaque burden for PDAPP mice. 
The current study found that PDAPP:E4 mice had worse behavioral deficits than 
PDAPP:E3 mice, and that these deficits were positively correlated with the degree of 
neuropathology. Several studies corroborate our findings such that amyloid load in mice 
is correlated with greater deficits in spatial learning tasks (G. Chen et al., 2000, Hartman 
et al., 2005, Hartman et al., 2006). Hartman et al., 2005 showed that these spatial learning 
deficits were ameliorated after treating transgenic mice with an antibody specific for 
human Aβ. Hartman et al., 2006 also showed that dietary supplementation with 
pomegranate juice decreased amyloid load and improve behavioral performance in 
transgenic mice. 
For example, higher amyloid plaque loads in the dorsal cortex of PDAPP:E3 mice 
were associated with lower activity levels (distance moved [Figure 17] and duration spent 
moving [Figure 18]) in the open field task. PDAPP:E3 mice also showed lower activity 
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levels in the zero maze, spending a lot of time in the dark. Although PDAPP:E3 mice 
spent more time in the dark than PDAPP:E4 mice, PDAPP:E3 still spent a relatively 
lower duration of time in the dark compared to control wild type mice who spend about 
2/3rds of that time in the dark. 
The current study also found that higher total Aβ loads in the hippocampi of 
PDAPP:E3 mice were correlated with better performance on the rotarod rotating at a 
steady rate, and higher total Aβ loads in the dorsal cortices of PDAPP:E4 mice were 
correlated with worse performance on the rotarod rotating at an accelerated rate. 
Contradictory to previous literature, one possible explanation for these results may be 
that Aβ accumulation may serve as a neuroprotective factor (e.g., by protecting cells from 
toxic protofibrils or oligomers) up until a substantial amount of balance and sensorimotor 
coordination is required (balancing on a rod rotating at an accelerated rate) in which case 
behavior declines, as observed in the findings.   
Correlation analyses between cell count and behavioral deficits confirmed that 
mice with more Alzheimer’s-like neuropathology have more behavioral deficits. 
Specifically, the degree of lower cellular density was positively correlated with deficits in 
spatial learning and memory. Similar findings were reported by Morris & Price (2001), in 
which they observed substantial cell loss in humans with mild AD. Multiple other studies 
then found that those with AD have behavioral deficits (Chen et al., 2000; Hartman et al., 
2005), providing evidence for the positive correlation between cell loss and behavioral 
deficits. 
PDAPP:E4 mice had more spatial learning deficits, spent more time in the open 
quadrants of the zero maze, and had worse performance on the rotarod than PDAPP:E3 
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mice. These findings were likely due to motor deficits and/or abnormal exploratory/risk-
taking behaviors.  
 
Limitations 
One main limitation of the current study is the low sample size. Many animals 
could not be included in the histological analysis due to high levels of old-age related 
mortality that often occurred overnight, rendering the brains difficult or impossible to 
process. This, in addition to the exclusion of outliers, yielded a low sample size that 
likely played a strong influence on high degree of variance observed. Further research is 
encouraged with a larger sample size. 
 
Conclusion 
The hypotheses for the current study, based on clinical observations in humans, 
was that PDAPP:E4 mice would have more Aβ plaques and lower cellular density in the 
CA1 and dorsal cortex than PDAPP:E3 mice, and that higher levels of neuropathology 
would be correlated with worse behavioral deficits.  
The findings from the current study partially corroborated those from Bales et al., 
1999 & 2009 in that diffuse Aβ was significantly greater in PDAPP:E4 mice than in 
PDAPP:E3 mice in the hippocampus and cortex. Although Bales et al., 1999 & 2009 also 
reported significant differences in fibrillar Aβ, the difference was not significant in the 
current study. The current study’s novel findings include significantly worse behavioral 
performance in the PDAPP:E4 mice, as well as a trend for PDAPP:E4 mice to have fewer 
 80 
cells per volume in both the hippocampus and cortex. Mice with more Alzheimer’s-like 
neuropathology generally had worse behavioral deficits. 
As illustrated in Table 5, various animal models for AD have been studied. The 
animal model from the current study (second to last row; Table 5) is the exact same 
animal model as the one studied in Bales et al., 1999 & 2009 (third to last row; Table 5.) 
The PDAPP:E mice in this study replicate several features of Alzheimer’s disease 
(last row; Table 5), and may therefore be a good model for studying how apoE genotype 
affects the development of the disease’s neuropathological and behavioral sequelae and 
its response to therapeutic treatments, especially those designed to reduce plaque 
accumulation. 
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Table 5. Summary of findings of various types of AD models and how they compare to 
the findings of the current study. 
    CA1 Dorsal Cortex     
Model Study 
Diff. 
Aβ 
Fibr. 
Aβ 
Lower 
Cell 
Density 
Diff. 
Aβ 
Fibr. 
Aβ 
Lower 
Cell 
Density Tau 
Beh. 
Deficits 
Humans 
with AD A ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
PDAPP B ✓ ✓ ✓ ✓ ✓ ✕ ✓ ✓ 
APP23, 
APP751, 
Tg2576, 
APP695, 
TG Mice C ✓ ✓ ✓ ✓ ✓ ✕ ✓ ✓ 
Human E4 
Mice D ✓ ✓ ✕ ✓ ✓ ✕ ✓ ✓ 
PSAPP, 
TASTPM 
Mice E ✕ ✓ ✓ ✕ ✓ ✓ ✓ ✓ 
PDAPP:E4 
Mice F ✓ ✓ ✕ ✕ ✕ Trend N/A Trend 
PDAPP:E4 
Mice (KI) G ✓ ✓ N/A ✓ ✓ N/A N/A N/A 
Current 
Model: 
PDAPP:E4 
Mice H ✓ ✕ Trend ✓ ✕ Trend N/A ✓ 
Combined 
Model I ✓ ✓ Trend ✓ ✓ Trend N/A ✓ 
Note.	"Diff."	=	diffuse,	"Fibr."	=	fibrillar,	"Beh."	=	Behavioral,	✓=	Present,	✕=	Absent,	N/A	=	Not	Tested;	A.	Bookheimer et al. 2000, Braak & Braak, 1995, Burggren et al., 
2008, Corder et al., 1993, & Schmechel et al., 1993; B. Duyckaerts et al., 2007, Games et 
al., 1995; German et al., 2005; Holtzman et al., 2000; C. Calhoun et al., 1998, Hartman et 
al., 2006, Hsiao et al., 1996, & Schmitz et al., 2004, Tomidokoro et al., 2001; D. Buttini 
et al., 2002, Grootendorst et al., 2005, Raber et al., 2004, Tesseur et al., 2000, & 
Tiraboschi et al., 2004; E. Holcomb et al., 1998,  Howlett et al., 2008, & Takeuchi et al., 
2000; F. Fagan et al., 2002 & Hartman et al., 2002; G. Bales et al., 1999 & Bales et al., 
2009; H. Current study; I. Bales et al., 1999, Bales et al., 2009, & Current study.	
  
 82 
REFERENCES 
Alzheimer’s Association. (2012). 2012 Alzheimer’s disease facts and figures. 
Alzheimer’s & Dementia, 8 (2). 
Alzheimer’s Association. (2014). 2014 Alzheimer’s disease facts and figures. 
Alzheimer’s & Dementia, 10 (2). 
Alvarez, R., Alvarez, V., Lahoz, C. H., Martínez, C., Peña, J., Sánchez, J. M., … Coto, E. 
(1999). Angiotensin converting enzyme and endothelial nitric oxide synthase DNA 
polymorphisms and late onset Alzheimer's disease. Journal Neurology 
Neurosurgery Psychiatry, 67, 733–736. 
Aly, H. F., Metwally, F. M., & Ahmed, H. H. (2011). Neuroprotective effects of 
dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta 
Biochimica Polonica (ABP), 58(4), 513–520. 
Aono, M., Bennett, E. ., Kim, K. ., Lynch, J. ., Myers, J., Pearlstein, R., … Laskowitz, D.  
(2003). Protective effect of apolipoprotein E-mimetic peptides on N-methyl-d-
aspartate excitotoxicity in primary rat neuronal–glial cell cultures. Neuroscience, 
116, 437–445.  
Asakawa, J., Takahashi, N., Rosenblum, B. B., & Neel, J. V. (1985). Two-dimensional 
gel studies of genetic variation in the plasma proteins of Amerindians and Japanese. 
Human Genetics, 70, 222–230. 
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., … Paul, S. M. (2009). 
Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP 
transgenic mice. The Journal of Neuroscience, 29(21), 6771–6779.  
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., … Paul, S. M. 
(1999). Apolipoprotein E is essential for amyloid deposition in the APP V717F 
transgenic mouse model of Alzheimer’s disease. Proceedings of the National 
Academy of Sciences of the United States of America, 96(26), 15233–15238. 
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., … Paul, S. M. 
(1997). Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. 
Nature Genetics, 17, 263–264. 
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007). Systematic 
meta-analyses of Alzheimer disease genetic association studies: The AlzGene 
database. Nature Genetics, 39(1), 17–23. 
Blacker, D., Wilcox, M. a, Laird, N. M., Rodes, L., Horvath, S. M., Go, R. C., … Tanzi, 
R. E. (1998). Alpha-2 macroglobulin is genetically associated with Alzheimer 
disease. Nature Genetics, 19(4), 357–60. 
Blue, M. L., Williams, D. L., Zucker, S., Khan, S. a, & Blum, C. B. (1983). 
 83 
Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proceedings 
of the National Academy of Sciences of the United States of America, 80(1), 283–7.  
Brinster, R. L., Chen, H. Y., Trumbauer, M., Senear,  A. W., Warren, R., & Palmiter, R. 
D. (1981). Somatic expression of herpes thymidine kinase in mice following 
injection of a fusion gene into eggs. Cell, 27, 223-231. 
Busciglio, J., Gabuzdat, D. H., Matsudairat, P., & Yankner, B. A. (1993). Generation of 
β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proceedings 
of the National Academy of Sciences of the United States of America, 90, 2092–2096. 
Calhoun, M. E., Wiederhold, K. H., Abramowski, D., Phinney,  a L., Probst, A., 
Sturchler-Pierrat, C., … Jucker, M. (1998). Neuron loss in APP transgenic mice. 
Nature, 395, 755–6. 
Capecchi, M. R. (1989). The new mouse genetics: Altering the genome by gene targeting. 
Trends in Genetics, 5(3). 
Casas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., … 
Pradier, L. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal 
truncated Aβ42 accumulation in a novel Alzheimer transgenic model. The American 
Journal of Pathology, 165(4), 1289–1300.  
Castellani, R. J., Lee, H., Siedlak, S. L., Nunomura, A., Hayashi, T., Nakamura, 
M.,…Smith, M. A. (2009). Reexamining Alzheimer's disease: Evidence for the 
protective role of amyloid-beta protein precursor and amyloid-beta. Journal of 
Alzheimer's Disease, 18(2), 447-452. 
Castello, M. A. & Soriano, S. (2013). Rational heterodoxy: Cholesterol reformation of 
the amyloid doctrine. Ageing Research Reviews, 12, 282-288. 
Castello, M. A., Jeppson, J. D., & Soriano, S. (2014). Moving beyond anti-amyloid 
therapy for the prevention and treatment of Alzheimer's disease. BMC Neurology, 
14(169). 
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., … Morris, R. G. M. 
(2000). A learning deficit related to age and b-amyloid plaques in a mouse model of 
Alzheimer’s disease. Nature, 408, 975–979. 
Chen, Y., Liang, Z., Blanchard, J., Dia, C., Sun, S., Lee, M. H., … Gong, C. (2013). A 
non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: Similarities 
to and difference from the transgenic model (3xTg-AD mouse). Molecular 
Neurobiology, 47(2), 711–725.  
Cheng, C.-Y., Hong, C.-J., Liu, H.-C., Liu, T.-Y., & Tsai, S.-J. (2002). Study of the 
association between Alzheimer's disease and angiotensin-converting enzyme gene 
polymorphism using DNA from lymphocytes. European Neurology, 47, 26–29. 
 84 
Christie, R. H., Chung, H., Rebeck, W., Strickland, D., & Hyman, B. (1996). Expression 
of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, 
in the central nervous system and in Alzheimer’s disease. Journal of 
Neuropathology and Experimental Neurology, 55(4), 491–498. 
Constantini, F., & Lacy, E. (1981). Introduction of a rabbit beta-globin gene into the 
mouse germ line. Nature, 294, 92–94. 
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., 
Small, G. W., … Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 
4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–
923. 
Cork, L. C., Powers, R. E., Selkoe, D. J., Davies, P., Geyer, J. J., & Price, D. L. (1988). 
Neurofibrillary tangles and senile plaques in aged bears. Journal of Neuropathology 
and Experimental Neurology, 47(6), 629–641. 
Croy, J. E., Brandon, T., & Komives, E. A. (2004). Two apolipoprotein E mimetic 
peptides, ApoE(130-149) and ApoE(141-155), bind to LRP1. Biochemistry, 43, 
7328–7335. 
Cummings, B. J., Head, E., Afagh, A. J., Milgram, N. W., & Cotman, C. W. (1996). β-
amyloid accumulation correlates with cognitive dysfunction in the aged canine. 
Neurobiology of Learning and Memory, 66, 11–23. 
Cummings, B. J., Head, E., Ruehl, W., Milgram, N. W., & Cotman, C. W. (1996). The 
canine as an animal model of human aging and dementia. Neurobiology of Aging, 
17(2), 259–268. 
DeMattos RB, Bales KR, Paul SM, et al. Potential role of endogenous and exogenous Ab 
binding molecules in Ab clearance and metabolism. In: Madame Curie Bioscience 
Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK6203/ 
 
Dickson, T. C., & Vickers, J. C. (2001). The morphological phenotype of beta-amyloid 
plaques and associated neuritic changes in Alzheimer’s Disease. Neuroscience, 
105(1), 99–107. 
 
Dodel, R. C., Y., D., Bales, K. R., Gao, F., Eastwood, B., Glazier, B., … Paul, S. M. 
(2000). α2 macroglobulin and the risk of Alzheimer’s disease. The American 
Academy of Neurology, 54, 438–442. 
Dow, D. J., Lindsey, N., Cairns, N. J., Brayne, C., Robinson, D., Huppert, F. A., … 
Rubinsztein, D. C. (1999). α-2 macroglobulin polymorphism and Alzheimer disease 
risk in the UK. Nature Genetics, 22, 16–17. 
Duyckaerts, C., Potier, M.-C., & Delatour, B. (2007). Alzheimer disease models and 
human neuropathology: Similarities and differences. Acta Neuropathologica, 115, 
 85 
5–38.  
Elder, G. A., Sosa, M. A. G., & Gasperi, R. De. (2010). Transgenic mouse models of 
Alzheimer’s disease. Mt. Sinai Journal, 77(1), 69–81.  
Elshourbagy, N. a, Liao, W. S., Mahley, R. W., & Taylor, J. M. (1985). Apolipoprotein E 
mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in 
other peripheral tissues of rats and marmosets. Proceedings of the National Academy 
of Sciences of the United States of America, 82, 203–207.  
Estus, S., Tucker, H. M., van Rooyen, C., Wright, S., Brigham, E. F., Wogulis, M., & 
Rydel, R. E. (1997). Aggregated amyloid-beta protein induces cortical neuronal 
apoptosis and concomitant “apoptotic” pattern of gene induction. The Journal of 
Neuroscience, 17(20), 7736–45.  
Eto, M., Watanabe, K., Iwashima, Y., Morikawa, A., Oshima, E., Sekiguchi, M., & Ishii, 
K. (1986). Apolipoprotein E polymorphism and hyperlipemia in type II diabetics. 
Diabetes, 35, 1374–1382. 
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. 
(2002). Human and murine apoE markedly alters A-beta metabolism before and 
after plaque formation in a mouse model of Alzheimer’s disease. Neurobiology of 
Disease, 9, 305–318. 
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., … 
van Duijn, C. M. (1997). Effects of age, sex, and ethnicity on the association 
between apolipoprotein E genotype and Alzheimer disease. JAMA, 278(16), 1349–
1356. 
Friedrich, R. P., Tepper, K., Rönicke, R., Soom, M., Westermann, M., Reymann, K., … 
Fändrich, M. (2010). Mechanism of amyloid plaque formation suggests an 
intracellular basis of A-beta pathogenicity. Proceedings of the National Academy of 
Sciences of the United States of America, 107(5), 1942–7.  
Fryer, J. D., Taylor, J. W., DeMattos, R. B., Bales, K. R., Paul, S. M., Parsadanian, M., & 
Holtzman, D. M. (2003). Apolipoprotein E markedly facilitates age-dependent 
cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor 
protein transgenic mice. The Journal of Neuroscience, 23(21), 7889–96.  
Games, D., Adams, D., Alessandrinl, R., Barbour, R., Bethelette, P., Blackwell, C., … 
Zhao, J. (1995). Alzheimer-type neuropathology in transgenic mice overexpressive 
V717F beta-amyloid precursor protein. Nature, 373, 523–527. 
Gomez-isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., … 
Hyman, B. T. (1997). Neuronal loss correlates with but exceeds neurofibrillary 
tangles in Alzheimer’s disease. American Neurological Association, 41(1), 17–24. 
Gordon, J. W., & Ruddle, F. H. (1981). Integration and stable germ line transmission of 
 86 
genes injected into mouse pronuclei. JSTOR, 214(4526), 1244–1246. 
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L. J., Younkin, L. H., … 
Younkin, S. G. (1995). Amyloid β protein (Aβ) in Alzheimer’s disease brain. The 
Journal of Biological Chemistry, 270(13), 7013–7016. 
Groen, T. V., Liu, L., Ikonen, S., & Kadish, I. (2003). Diffuse amyloid deposition, but 
not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-
transgenic mice by pathway lesions. Neuroscience, 119, 1185–1197.  
Grootendorst, J., Bour, A., Vogel, E., Kelche, C., Sullivan, P. M., Dodart, J.-C., … 
Mathis, C. (2005). Human apoE targeted replacement mouse lines: h-apoE4 and h-
apoE3 mice differ on spatial memory performance and avoidance behavior. 
Behavioural Brain Research, 159, 1–14.  
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., 
Ostaszewski, B. L., … Selkoe, D. J. (1992). Amyloid beta-peptide is produced by 
cultured cells during normal metabolism. Nature, 359, 322–325. 
Harkany, T., Hortobagyi, T., Sasvari, M., Konya, C., Penke, B., Luiten, P. G. M., & 
Nyakas, C. (1999). Neuroprotective approaches in experimental models of β-
amyloid neurotoxicity: Relevance to Alzheimer’s disease. Progress in Neuro-
Psychopharmacology & Biological Psychiatry, 23, 963–1008. 
Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., & Holtzman, D. M. 
(2005). Treatment with an amyloid-beta antibody ameliorates plaque load, learning 
deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s 
disease. The Journal of Neuroscience, 25(26), 6213–20.  
Hartman, R. E., Laurer, H., Longhi, L., Bales, K. R., Paul, S. M., Mcintosh, T. K., & 
Holtzman, D. M. (2002). Apolipoprotein E4 influences amyloid deposition but not 
cell loss after traumatic brain injury in a mouse model of alzheimer's disease. The 
Journal of Neuroscience, 22(23), 10083–10087. 
Hartman, R. E., Shah, A., Fagan, A. M., Schwetye, K. E., Parsadanian, M., Schulman, R. 
N., … Holtzman, D. M. (2006). Pomegranate juice decreases amyloid load and 
improves behavior in a mouse model of Alzheimer’s disease. Neurobiology of 
Disease, 24, 506–15.  
Hartman, R. E., Wozniak, D. F., Nardi, A., Olney, J. W., Sartorius, L., & Holtzman, D. M. 
(2001). Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: 
ApoE4 mice show profound working memory impairments in the absence of 
Alzheimer’s-like neuropathology. Experimental Neurology, 170, 326–344. 
Head, E., McCleary, R., Hahn, F. F., Milgram, N. W., & Cotman, C. W. (2000). Region-
specific age at onset of beta-amyloid in dogs. Neurobiology of Aging, 21, 89–96.  
Holtzman, D. (2004). In vivo effects of apoE and clusterin on amyloid-β metabolism and 
 87 
neuropathology. Journal of Molecular Neuroscience, 23, 247–254. 
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan,  a M., Parsadanian, M., Sartorius, L. 
J., … Paul, S. M. (2000). Apolipoprotein E isoform-dependent amyloid deposition 
and neuritic degeneration in a mouse model of Alzheimer’s disease. Proceedings of 
the National Academy of Sciences of the United States of America, 97(6), 2892–7.  
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., … Paul, 
S. M. (1999). Expression of human apolipoprotein E reduces amyloid-β deposition 
in a mouse model of Alzheimer’s disease. The Journal of Clinical Investigation, 
103(6), 15–21. 
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., … Cole, G. 
(1996). Correlative memory deficits, Aβ evelation, and amyloid plaques in 
transgenic mice. Science, 274, 99–102. 
Hu, J., Miyatake, F., Aizu, Y., Nakagawa, H., Nakamura, S., Tamaoka, A., … Shoji, M. 
(1999). Angiotensin-converting enzyme genotype is associated with Alzheimer 
disease in the Japanese population. Neuroscience Letters, 277, 65–7.  
Hyman, B. T., Tanzi, R. E., Marzloff, K., Barbour, R., & Schenk, D. (1992). Kunitz 
protease inhibitor-containing amyloid β protein precursor immunoreactivity in 
Alzheimer’s disease. Journal of Neuropathological Experimental Neurology, 51(1), 
76–83. 
Irizarry, M. C., Cheung, B. S., Rebeck, G. W., Paul, S. M., Bales, K. R., & Hyman, B. T. 
(2000). Apolipoprotein E affects the amount, form, and anatomical distribution of 
amyloid beta-peptide deposition in homozygous APPV717F transgenic mice. Acta 
Neuropathologica, 100, 451–8 
Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & 
Hyman, B. T. (1997). Abeta deposition is associated with neuropil changes, but not 
with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) 
transgenic mouse. The Journal of Neuroscience, 17(18), 7053–9.  
Jacque, C. M., Vinner, C., Kujas, M., Raoul, M., Racadot, J., & Baumann, N. A. (1978). 
Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. 
Journal of the Neurological Sciences, 35, 147–155. 
Jaenisch, R., & Mintz, B. (1974). Simian virus 40 DNA sequences in DNA of healthy 
adult mice derived from preimplantation blastocysts injected with viral DNA. PNAS, 
71(4), 1250–1254. 
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The carboxy terminus of the .beta. 
amyloid protein is critical for the seeding of amyloid formation: Implications for the 
pathogenesis of Alzheimer’s disease. Biochemistry, 32(18), 4693–4697.  
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. a, & Wirths, O. (2012). Motor 
 88 
deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and 
intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer’s disease. 
Neurobiology of Aging, 33, 196.e29–40. 
Ji, Z.-S., Miranda, R. D., Newhouse, Y. M., Weisgraber, K. H., Huang, Y., & Mahley, R. 
W. (2002). Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal 
leakage and apoptosis in neuronal cells. The Journal of Biological Chemistry, 
277(24), 21821–8.  
Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., … 
McConlogue, L. (1997). Amyloid precursor protein processing and Abeta42 
deposition in a transgenic mouse model of Alzheimer disease. Proceedings of the 
National Academy of Sciences of the United States of America, 94, 1550–1555. 
Johnstone, E. M., Chaney, M. O., & Norris, F. H. (1991). Conservation of the sequence 
of the Alzheimer's disease amyloid peptide in dog, polar bear and five other 
mammals by cross-species polymerase chain reaction analysis. Molecular Brain 
Research, 10, 299–305. 
Joseph, J. a, Denisova, N. a, Arendash, G., Gordon, M., Diamond, D., Shukitt-Hale, B., & 
Morgan, D. (2003). Blueberry supplementation enhances signaling and prevents 
behavioral deficits in an Alzheimer disease model. Nutritional Neuroscience, 6(3), 
153–62. 
Kamboh, M. I., Ferrell, R. E., & DeKosky, S. T. (1998). Genetic association studies 
between Alzheimer’s disease and two polymorphisms in the low density lipoprotein 
receptor-related protein gene. Neuroscience Letters, 244, 65–68.  
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., … Point, 
W. (2003). APP processing and synaptic function. Neuron, 37, 925–937. 
Kang, D. E., Saitoh, T., Chen, X., Xia, Y., Masliah, E., Hansen, L. a., … Katzman, R. 
(1997). Genetic association of the low-density lipoprotein receptor-related protein 
gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer’s disease. 
Neurology, 49, 56–61. 
Kehoe, P. G., Russ, C., Mcilroy, S., Williams, H., Holmans, P., Holmes, C., … Owen, M. 
J. (1999). Variation in DCP1, encoding ACE, is associated with susceptibility to 
Alzheimer disease. Nature Genetics, 21, 71–72. 
Kenney, J. M., Knight, D., Wise, M. J., & Vollrath, F. (2002). Amyloidogenic nature of 
spider silk. European Journal of Biochemistry, 269, 4159–4163.  
Kim, J., Basak, J. M., & Holtzman, D. M. (2009). The role of apolipoprotein E in 
Alzheimer’s disease. Neuron, 63, 287–303.  
Koudinov, A. R., Berezov, T. T., & Koudinova, N. V. (2001). Amyloid plaque (and not 
diffuse amyloid) is a condition for neuronal dysfunction. Clinical Medicine & 
 89 
Health Research. 
Kounnas, M. Z., Moir, R. D., Rebeck, G. W., Bush,  a I., Argraves, W. S., Tanzi, R. E., 
… Strickland, D. K. (1995). LDL receptor-related protein, a multifunctional apoE 
receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. 
Cell, 82, 331–40.  
LaFerla, F. M., Hall, C. K., Ngo, L., & Jay, G. (1996). Extracellular deposition of beta-
amyloid upon p53-dependent neuronal cell death in transgenic mice. The Journal of 
Clinical Investigation, 98(7), 1626–32.  
Lamb, B. T., Sisodia, S. S., Lawler, A. M., Slunt, H. H., Kitt, C. A., Kearns, W. G., … 
Gearhart, J. D. (1993). Introduction and expression of the 400 kilobase precursor 
amyloid protein gene in transgenic mice. Nature Genetics, 5, 22–30. 
Laskowitz, D. T., Fillit, H., Yeung, N., Toku, K., & Vitek, M. P. (2006). Apolipoprotein 
E-derived peptides reduce CNS inflammation: Implications for therapy of 
neurological disease. Acta Neurologica Scandinavica Supplementum, 114, 15–20.  
Laskowitz, D. T., McKenna, S. E., Song, P., Wang, H., Durham, L., Yeung, N., … Vitek, 
M. P. (2007). COG1410, a novel apolipoprotein E-based peptide, improves 
functional recovery in a murine model of traumatic brain injury. Journal of 
Neurotrauma, 24(7), 1093–107.  
Laskowitz, D. T., Thekdi,  a D., Thekdi, S. D., Han, S. K., Myers, J. K., Pizzo, S. V, & 
Bennett, E. R. (2001). Downregulation of microglial activation by apolipoprotein E 
and apoE-mimetic peptides. Experimental Neurology, 167, 74–85.  
Lecanu, L., Greeson, J., & Papadopoulos, V. (2006). Beta-amyloid and oxidative stress 
jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in 
the rat brain. Pharmacology, 76, 19–33. 
Lemere, C. a, Oh, J., Stanish, H. a, Peng, Y., Pepivani, I., Fagan, A. M., … Mansfield, K. 
G. (2008). Cerebral amyloid-beta protein accumulation with aging in cotton-top 
tamarins: A model of early Alzheimer’s disease? Rejuvenation Research, 11(2), 
321–32. 
Lendon, C. L., J. Talbot, C., Craddock, N. J., Woo Han, S., Wragg, M., Morris, J. C., & 
Goate, A. M. (1997). Genetic association studies between dementia of the 
Alzheimer’s type and three receptors for apolipoprotein E in a Caucasian population. 
Neuroscience Letters, 222, 187–190. 
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. a, & Cole, G. M. (2001). The 
curry spice curcumin reduces oxidative damage and amyloid pathology in an 
Alzheimer transgenic mouse. The Journal of Neuroscience, 21(21), 8370–7.  
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., … Cole, G. M. (2000). 
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for 
 90 
Alzheimer's disease. The Journal of Neuroscience, 20(15), 5709–5714. 
Lim, Y.-W., Yoon, S.-Y., Choi, J.-E., Kim, S.-M., Lee, H.-S., Choe, H., … Kim, D.-H. 
(2010). Maintained activity of glycogen synthase kinase-3β despite of its 
phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. 
Biochemical and Biophysical Research Communications, 395, 207–12.  
Loo, D. T., Copani,  a, Pike, C. J., Whittemore, E. R., Walencewicz,  a J., & Cotman, C. 
W. (1993). Apoptosis is induced by β-amyloid in cultured central nervous system 
neurons. Proceedings of the National Academy of Sciences of the United States of 
America, 90, 7951–5.  
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-khan, S., Denis, P., … Vassar, R. 
(2001). Mice deficient in BACE1, the Alzheimer’s β-secretase, have normal 
phenotype and abolished β-amyloid generation. Nature Neuroscience, 4(3), 231–232. 
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., … Wu, H. 
(2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. 
Science, 304, 448–52.  
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., … 
Laskowitz, D. T. (2003). APOE genotype and an apoE-mimetic peptide modify the 
systemic and central nervous system inflammatory response. The Journal of 
Biological Chemistry, 278(49), 48529–33.  
Lynch, J. R., Wang, H., Mace, B., Leinenweber, S., Warner, D. S., Bennett, E. R., … 
Laskowitz, D. T. (2005). A novel therapeutic derived from apolipoprotein E reduces 
brain inflammation and improves outcome after closed head injury. Experimental 
Neurology, 192, 109–116. 
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006). Apolipoprotein E4: A causative 
factor and therapeutic target in neuropathology, including Alzheimer’s disease. 
Proceedings of the National Academy of Sciences of the United States of America, 
103(15), 5644–51. 
Mann, D. M. A. (1996). Pyramidal nerve cell loss in Alzheimer’s disease. 
Neurodegeneration, 5, 423–427.  
Martin, B. L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P., & Yankner, B. 
a. (1995). Intracellular accumulation of  β-amyloid in cells expressing the swedish 
mutant amyloid precursor protein. Journal of Biological Chemistry, 270(45), 26727–
26730. 
Matsubara, E., Bryant-Thomas, T., Pacheco Quinto, J., Henry, T. L., Poeggeler, B., 
Herbert, D., … Pappolla, M. a. (2003). Melatonin increases survival and inhibits 
oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. 
Journal of Neurochemistry, 85, 1101–1108.  
 91 
Mattson, M. P. (1997). Cellular actions of β-amyloid precursor protein and its soluble and 
fibrillogenic derivatives. Physiological Reviews, 77(4), 1081–132.  
Mattson, M. P., Partin, J., & Begley, J. G. (1998). Amyloid β-amyloid induces apoptosis-
related events in synapses and dendrites. Brain Research, 807, 167–76.  
McAdoo, J. D., Warner, D. S., Goldberg, R. N., Vitek, M. P., Pearlstein, R., & Laskowitz, 
D. T. (2005). Intrathecal administration of a novel apoE-derived therapeutic peptide 
improves outcome following perinatal hypoxic-ischemic injury. Neuroscience 
Letters, 381, 305–8.  
McIlroy, S. P., Vahidassr, M. D., Savage, D. A., Patterson, C. C., Lawson, J. T., & 
Passmore, A. P. (1999). Risk of Alzheimer's disease is associated with a very low-
density lipoprotein receptor genotype in northern Ireland. American Journal of 
Medical Genetics (Neuropsychiatric Genetics), 88, 140–144. 
Mori, H., Takio, K., Ogawarag, M., & Selkoe, D. J. (1992). Mass spectrometry of 
purified amyloid beta protein in Alzheimer’s disease. Journal of Biological 
Chemistry, 267(24), 17082–17086. 
Morris, J. C., & Price, J. L. (2001). Pathologic correlates of nondemented aging, mild 
cognitive impairment, and early-stage Alzheimer’s disease. Journal of Molecular 
Neuroscience, 17, 101–118. 
Nakamura, S., Murayama, N., Noshita, T., Annoura, H., & Ohno, T. (2001). Progressive 
brain dysfunction following intracerebroventricular infusion of beta1-42-amyloid 
peptide. Brain Research, 912, 128–36.  
Näslund, J., Schierhorn,  a, Hellman, U., Lannfelt, L., Roses,  a D., Tjernberg, L. O., … 
Greengard, P. (1994). Relative abundance of Alzheimer Aβ amyloid peptide variants 
in Alzheimer disease and normal aging. Proceedings of the National Academy of 
Sciences of the United States of America, 91, 8378–82.  
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., … Vassar, R. (2006). 
Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in 
transgenic mice with five familial Alzheimer’s disease mutations: potential factors 
in amyloid plaque formation. The Journal of Neuroscience, 26(40), 10129–40.  
Okuizumi, K., Onodera, O., Namba, Y., Ikeda, K., Yamamoto, T., Seki, K., … Tsuji, S. 
(1995). Genetic association of the very low density lipprotein (VLDL) receptor gene 
with sporadic Alzheimer’s disease. Nature Genetics, 11, 207–209. 
Okuizumi, K., Onodera, O., Seki, K., Tanaka, H., Namba, Y., Ikeda, K., … Tsuji, S. 
(1996). Lack of association of verv low densitv Lipoprotein receptor gene 
polymorphism with Caucasian Alzheimer’s disease. American Neurological 
Association, 40(2), 251–254. 
Ordovas, J. M., Litwack-klein, L., Schaefer, E. J., Study, F. H., Heart, N., & Street, L. 
 92 
(1987). Apolipoprotein E isoform phenotyping methodology and population 
frequency with identification of apoEl and apoE5 isoforms. Journal of Lipid 
Research, 28, 371–380. 
Oriá, R. B., Patrick, P. D., Zhang, H., Lorntz, B., de Castro Costa, C. M., Brito, G. a C., 
… Guerrant, R. L. (2005). APOE4 protects the cognitive development in children 
with heavy diarrhea burdens in northeast Brazil. Pediatric Research, 57(2), 310–6.  
Pericak-vance, M. A., Bass, M. P., Yamaoka, L. H., Gaskell, P. C., Scott, W. K., 
Terwedow, H. A., … Haines, J. L. (1997). Complete genomic screen in late-onset 
familial Alzheimer disease. JAMA, 278(15), 1237–1241. 
Poirier, J. (1996). Apolipoprotein E in the brain and its role in Alzheimer’s disease. 
Journal Psychiatry Neuroscience, 21(2), 128–134. 
Pop, V., Sorensen, D. W., Kamper, J. E., Ajao, D. O., Paul Murphy, M., Head, E., … 
Murphy, P. M. (2012). Early brain injury alters the blood – brain barrier phenotype 
in parallel with beta-amyloid and cognitive changes in adulthood. Journal of 
Cerebral Blood Flow & Metabolism, 1–10.  
Querfurth, H. W., & Laferla, F. M. (2010). Mechanisms of disease: Alzheimer’s disease. 
The New England Journal of Medicine, 362(4), 329–344. 
Quon, D., Wang, Y., Catalano, R., Scardina, J. M., Murakami, K., & Cordell, B. (1991). 
Formation of the beta-amyloid protein deposits in brains of transgenic mice. Nature, 
352, 239–241. 
Rambaran, R. N., & Serpell, L. C. (2008). Amyloid fibrils: Abnormal protein assembly. 
Prion, 2(3), 112–7.  
Rebeck, C. W., Reiter, J. S., Strickland, D. K., Hyman, B., & Cross, R. (1993). 
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor 
interactions. Neuron, 11, 575–580. 
Reddy, P. H. (2009). Amyloid beta, mitochondrial structural, and functional dynamics in 
Alzheimer’s disease. Experimental Neurology, 218(2), 286–292.  
Rocchi, A., Pellegrini, S., Siciliano, G., & Murri, L. (2003). Causative and susceptibility 
genes for Alzheimer’s disease: A review. Brain Research Bulletin, 61, 1–24.  
Rogaeva, E. a, Premkumar, S., Grubber, J., Serneels, L., Scott, W. K., Kawarai, T., … 
Pericak-Vance, M. a. (1999). An alpha-2-macroglobulin insertion-deletion 
polymorphism in Alzheimer disease. Nature Genetics, 22, 19–22.  
Roher,  a. E., Chaney, M. O., Kuo, Y.-M., Webster, S. D., Stine, W. B., Haverkamp, L. J., 
… Emmerling, M. R. (1996). Morphology and toxicity of Aβ-(1-42) dimer derived 
from neuritic and vascular amyloid deposits of Alzheimer’s disease. Journal of 
Biological Chemistry, 271(34), 20631–20635. 
 93 
Roher, A. E., Kokjohn, T. a, Esh, C., Weiss, N., Childress, J., Kalback, W., … Ghetti, B. 
(2004). The human amyloid-β precursor protein770 mutation V717F generates 
peptides longer than amyloid-β-(40-42) and flocculent amyloid aggregates. The 
Journal of Biological Chemistry, 279(7), 5829–36.  
Sarasa, M., & Pesini, P. (2009). Natural non-trasgenic animal models for research in 
Alzheimer’s disease. Current Alzheimer’s Research, 6, 171–178. 
Schellenberg, G. D. (1995). Progress in Alzheimer’s disease genetics. Current Opinion in 
Neurology, 8, 262–267. 
Schmechel, D. E., Saunders,  a M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. 
H., … Roses,  a D. (1993). Increased amyloid β-peptide deposition in cerebral cortex 
as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. 
Proceedings of the National Academy of Sciences of the United States of America, 
90, 9649–53.  
Schmitz, C., Rutten, B. P. F., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., … Bayer, T. 
a. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic 
mouse model of Alzheimer’s disease. The American Journal of Pathology, 164(4), 
1495–502. 
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Lillian, M., … Younkint, S. G. 
(2014). Production of the Alzheimer amyloid β protein by normal proteolytic 
processing. Science, 258(5079), 126–129. 
Stéphan, A., Laroche, S., & Davis, S. (2001). Generation of aggregated β-amyloid in the 
rat hippocampus impairs synaptic transmission and plasticity and causes memory 
deficits. The Journal of Neuroscience, 21(15), 5703–14.  
Stern, E. a, Bacskai, B. J., Hickey, G. a, Attenello, F. J., Lombardo, J. a, & Hyman, B. T. 
(2004). Cortical synaptic integration in vivo is disrupted by amyloid-β plaques. The 
Journal of Neuroscience, 24(19), 4535–40.  
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., … 
Maeda, N. (1997). Targeted replacement of the mouse apolipoprotein E gene with 
the common human APOE3 allele enhances diet-induced hypercholesterolemia and 
atherosclerosis. Journal of Biological Chemistry, 272(29), 17972–17980.  
Suzuki, N., Cheung, T. T., Cai, X., Odaka, A., Jr, L. O., Eckman, C., … Younkint, S. G. 
(1994). An increased percentage of long amyloid β protein secreted by familial 
amyloid β protein precursor (βAPP717). Science, 264, 1336–1340. 
Tai, L. M., Youmans, K. L., Jungbauer, L., Yu, C., & Ladu, M. J. (2011). Introducing 
human APOE into Aβ transgenic mouse models. International Journal of 
Alzheimer’s Disease, 2011, 810981.  
Takeuchi, A., Irizarry, M. C., Duff, K., Saido, T. C., Hsiao Ashe, K., Hasegawa, M., … 
 94 
Iwatsubo, T. (2000). Age-related amyloid β deposition in transgenic mice 
overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein 
Swedish mutant is not associated with global neuronal loss. The American Journal 
of Pathology, 157(1), 331–339. 
Tiraboschi, P., Hansen, L. a., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. 
(2004). Impact of APOE genotype on neuropathologic and neurochemical markers 
of Alzheimer disease. Neurology, 62, 1977–1983.  
Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., … Ghiso, J. 
(2000). Lipidation of apolipoprotein E influences its isoform-specific interaction 
with Alzheimer’s amyloid β peptides. Biochem. J., 348, 359–365. 
Tran, H. T., Sanchez, L., Esparza, T. J., & Brody, D. L. (2011). Distinct temporal and 
anatomical distributions of amyloid-β and tau abnormalities following controlled 
cortical impact in transgenic mice. PloS One, 6(9), 1-8.  
Tsuchiya, S., Yamanouchi, Y., Onuki, M., Yamakawa, K., Miyazaki, R., Taya, T., … 
Hamaguchi, H. (1985). Frequencies of apolipoproteins E5 and E7 in apparently 
healthy Japanese. Jpn. J. Human Genet., 30, 271–278. 
Utermann, G. (1982). Apolipoprotein E (role in lipoprotein metabolism and 
pathophysiology of hyperlipoproteinemia type III). La Ricerca in clinica e in 
laboratorio, 12, 23–30. 
Venkatesh, K., Srikanth, L., Vengamma, B., Chandrasekhar, C., Sanjeevkumar, A., 
Mouleshwara Prasad, B. C., & Sarma, P. V. G. K. (2013). In vitro differentiation of 
cultured human CD34+ cells into astrocytes. Neurology India, 61(4), 383–8.  
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011). Roles of apolipoprotein E 
in Alzheimer’s disease and other neurological disorders. Lanect Neurology, 10(3), 
241–252.  
Vitek, M. P., Christensen, D. J., Wilcock, D., Davis, J., Van Nostrand, W. E., Li, F. Q., & 
Colton, C. a. (2012). APOE-mimetic peptides reduce behavioral deficits, plaques 
and tangles in Alzheimer’s disease transgenics. Neuro-Degenerative Diseases, 10, 
122–6. 
Wahrle, S., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S., & 
Holtzman, D. M. (2005). Deletion of Abca1 increases Aβ deposition in the PDAPP 
transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry, 
280(52), 43236–43242. 
Weisgraber, K. H., Rail, S. C., Innerarity, T. L., & Mahley, R. W. (1984). A novel 
electrophoretic variant of apolipoprotein El. Journal of Clinical Investigation, 73, 
1024–1033. 
Wertkin, A. M., Turner, R. S., Pleasure, S. J., Golde, T. E., Younkin, S. G., Trojanowski, 
 95 
J. Q., & Lee, V. M. (1993). Human neurons derived from a teratocarcinoma cell line 
express solely the 695-amino acid amyloid precursor protein and produce 
intracellular β-amyloid or A4 peptides. Proceedings of the National Academy of 
Sciences of the United States of America, 90, 9513–7.  
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994). Differences in the 
pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. The 
Lacet, 344, 769–72. 
Yamamura, T., Yamamoto, A., & Sumiyoshi, T. (1984). New mutants of apolipoprotein 
E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia. 
Journal of Clinical Investigation, 74, 1229–1237. 
Yan, Y., & Wang, C. (2006). Aβ42 is more rigid than Aβ40 at the C terminus: 
Implications for Aβ aggregation and toxicity. Journal of Molecular Biology, 364, 
853-862. 
Yang, A. J., Knauer, M., Burdick, D. A., & Glabe, C. (1995). Intracellular Aβ1-42 
aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments 
of the amyloid precursor protein in transfected cells. The Journal of Biological 
Chemistry, 270(24), 14876–14792. 
Yao, J., Petanceska, S. S., Montine, T. J., Holtzman, D. M., Schmidt, S. D., Parker, C. a, 
… Gandy, S. (2004). Aging, gender and APOE isotype modulate metabolism of 
Alzheimer’s Aβ peptides and F2-isoprostanes in the absence of detectable amyloid 
deposits. Journal of Neurochemistry, 90, 1011–8.  
Ye, S., Huang, Y., Mullendorff, K., Dong, L., Giedt, G., Meng, E. C., … Mahley, R. W. 
(2005). Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured 
neuronal cells: ApoE structure as a potential therapeutic target. Proceedings of the 
National Academy of Sciences of the United States of America, 102(51), 18700–
18705. 
Younkin, S. G. (1998). The role of Aβ-42 in Alzheimer’s disease. Journal of Physiology, 
92, 289–292. 
 
